AU4288499A - Creation of Inventions and Patents with Artificial Intelligence

AU4288499A – Conformationally constrained backbone cyclized somatostatin analogs
– Google Patents

AU4288499A – Conformationally constrained backbone cyclized somatostatin analogs
– Google Patents
Conformationally constrained backbone cyclized somatostatin analogs

Download PDF
Info

Publication number
AU4288499A

AU4288499A
AU42884/99A
AU4288499A
AU4288499A
AU 4288499 A
AU4288499 A
AU 4288499A
AU 42884/99 A
AU42884/99 A
AU 42884/99A
AU 4288499 A
AU4288499 A
AU 4288499A
AU 4288499 A
AU4288499 A
AU 4288499A
Authority
AU
Australia
Prior art keywords
phe
trp
thr
ala
lys
Prior art date
1998-06-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU42884/99A
Other versions

AU747515B2
(en

Inventor
Michel M. Afargan
Gary Gellerman
Vered Hornik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cortendo AB

Original Assignee
Cortendo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1998-06-19
Filing date
1999-06-15
Publication date
2000-01-05

1998-06-19
Priority claimed from US09/100,360
external-priority
patent/US6051554A/en

1999-06-15
Application filed by Cortendo AB
filed
Critical
Cortendo AB

2000-01-05
Publication of AU4288499A
publication
Critical
patent/AU4288499A/en

2002-05-16
Application granted
granted
Critical

2002-05-16
Publication of AU747515B2
publication
Critical
patent/AU747515B2/en

2016-02-18
Assigned to CORTENDO AB
reassignment
CORTENDO AB
Alteration of Name(s) in Register under S187
Assignors: PEPTOR LTD.

2019-06-15
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/575—Hormones

C07K14/655—Somatostatins

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/575—Hormones

C07K14/655—Somatostatins

C07K14/6555—Somatostatins at least 1 amino acid in D-form

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P25/00—Drugs for disorders of the nervous system

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P3/00—Drugs for disorders of the metabolism

A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P35/00—Antineoplastic agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P37/00—Drugs for immunological or allergic disorders

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

G—PHYSICS

G01—MEASURING; TESTING

G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES

G01R31/00—Arrangements for testing electric properties; Arrangements for locating electric faults; Arrangements for electrical testing characterised by what is being tested not provided for elsewhere

G01R31/28—Testing of electronic circuits, e.g. by signal tracer

G01R31/317—Testing of digital circuits

G01R31/3181—Functional testing

G01R31/31816—Soft error testing; Soft error rate evaluation; Single event testing

G—PHYSICS

G01—MEASURING; TESTING

G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES

G01R31/28—Testing of electronic circuits, e.g. by signal tracer

G01R31/317—Testing of digital circuits

G01R31/3181—Functional testing

G01R31/3185—Reconfiguring for testing, e.g. LSSD, partitioning

G01R31/318533—Reconfiguring for testing, e.g. LSSD, partitioning using scanning techniques, e.g. LSSD, Boundary Scan, JTAG

G01R31/318541—Scan latches or cell details

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

Abstract

Methods of use of pharmaceutical compositions and novel peptides which are conformationally constrained backbone cyclized somatostatin analogs, having somatostatin receptor subtype selectivity, are disclosed. These patterns or receptor subtype selectivity provide compounds having improved therapeutic utility. Methods for synthesizing the somatostatin analogs and for screening of the somatostatin analogs are also disclosed. Furthermore, pharmaceutical compositions comprising somatostatin analogs are disclosed.

Description

WO99/65508 PCT/IL99/00329 CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN ANALOGS 5 FIELD OF THE INVENTION The present invention relates to conformationally constrained No backbone-cyclized somatostatin analogs cyclized via novel linkages, and to pharmaceutical compositions containing same. 10 BACKGROUND OF THE INVENTION Somatostatin analogs Somatostatin is a cyclic tetradecapeptide found both in the central nervous system and in peripheral tissues. It was 15 originally isolated from mammalian hypothalamus and identified as an important inhibitor of growth hormone secretion from the anterior pituitary. Its multiple biological activities include inhibition of the secretion of glucagon and insulin from the pancreas, regulation of most 20 gut hormones and regulation of the release of other neurotransmitters involved in motor activity and cognitive processes throughout the central nervous system (for review see Lamberts, Endocrine Rev., 9:427, 1988). Additionally, somatostatin and its analogs are potentially useful 25 antiproliferative agents for the treatment of various types of tumors. Natural somatostatin (also known as Somatotropin Release Inhibiting Factor, SRIF) having the following structure: 1 2 3 4 5 6 7 8 9 10 11 12 H-Ala -Gly2-CyS3-Lys -Asn -Phe -Phe -Trp -Lys -Thrl -Phe -Thr -2 30 Ser 13-Cys -OH was first isolated by Guillemin and colleagues (Bruzeau et al. Science, 179:78, 1973). It exerts its effects by interacting with a family of receptors. Recently, five receptor subtypes, termed SST-R1 to 5, have been identified 35 and cloned. The precise functional distinction between these receptor subtypes has not yet been fully elucidated. – 1 – WO99/65508 PCT/IL99/00329 In its natural form, somatostatin has limited use as a therapeutic agent since it exhibits two undesirable properties: poor bioavailability and short duration of action. For this reason, great efforts have been made during 5 the last two decades to find somatostatin analogs that will have superiority in either potency, biostability, duration of action or selectivity with regard to inhibition of the release of growth hormone, insulin or glucagon. Structure-activity relation studies, spectroscopic techniques 10 such as circular dichroism and nuclear magnetic resonance, and molecular modeling approaches reveal the following: the conformation of the cyclic part of natural somatostatin is most likely to be an antiparallel P-sheet; Phe 6 and Phe 1 ” play an important role in stabilizing the pharmacophore 15 conformation through hydrophobic interactions between the two aromatic rings; the four amino acids Phe 7 -Trp 9 -Lys 9 -Thr 1 u which are spread around the P-turn in the antiparallel -sheet are essential for the pharmacophore; and (D)Trp 8 is preferable to (L)Trp 8 for the interactions with somatostatin 20 receptor subtypes 2 through 5. Nevertheless, a hexapeptide somatostatin analog containing these four amino acids anchored by a disulfide bridge: Cys-Phe -(D)Trp -Lys -Thrlo-Cys 25 is almost inactive both in-vitro and in-vivo, although it has the advantage of the covalent disulfide bridge which replaces 30 the Phe 6 -Phe 11 hydrophobic interactions in natural somatostatin. Four main approaches have been attempted in order to increase the activity of this hexapeptide somatostatin analog. (1) Replacing the disulfide bridge by a cyclization which 35 encourages a cis-amide bond, or by performing a second cyclization to the molecule yielding a bicyclic analog. In both cases the resultant analog has a reduced number of – 2 – WO99/65508 PCT/IL99/00329 conformational degrees of freedom. (2) Replacing the original residues in the sequence Phe -(D)Trp -Lys -Thr ° with other natural or non-natural amino acids, such as replacing Phe with Tyr and Thrlo with Vallo. (3) Incorporating 5 additional functional groups from natural somatostatin with the intention that these new elements will contribute to the interaction with the receptor. (4) Eliminating one of the four amino acids Phe -(D)Trp -Lys -Thr1o with the assumption that such analogs would be more selective. 10 The somatostatin analog, MK-678: cyclo(N-Me-Ala 6-Tyr 7 -(D)Trp 8 -Lys 9 -Val 1 o-Phe) is an example of a highly potent somatostatin analog designed 15 using the first three approaches above (Veber, et al., Life Science, 34:371, 1984). In this hexapeptide analog, a cis-amide bond is located between N-Me-Ala and Phe 11 , Tyr 7 and Val’ 0 replace Phe 7 and Thrlo respectively, and Phe 11 is incorporated from natural somatostatin. 20 Another group of somatostatin analogs (U.S. patents 4,310,518 and 4,235,886) includes Octreotide: H-(D)Phes-Cys-Phe -(D)Trp8-Lys -Thrl o-Cys-Thr 2-CH 2 0H 25 the first approved somatostatin analog clinically available. It was developed using the third approach described above. Here, (D)Phe 5 and the reduced C-terminal Thr2-CH 2 OH are 30 assumed to occupy some of the conformational space available 6 12 to the natural Phe and Thr , respectively. The compound TT-232: 35 H-(D)Phe-Cys-Phe 7 -(D)Trp 8 -Lys 9 -C s-Thr-NH2 – 3 – WO99/65508 PCT/IL99/00329 is closely related to Octreotide and is an example of implementing the fourth approach described above. The lack of Thrlo is probably responsible for its high functional 5 selectivity in terms of antitumor activity. These examples of highly potent somatostatin analogs suggest that the phenylalanines in positions 6 and 11 not only play an important role in stabilizing the pharmacophore conformation but also have a functional role in the 10 interaction with the receptor. It is still an open question whether one phenylalanine (either Phe 6 or Phe”) is sufficient for the interaction with the receptor or whether both are needed. It is now known that the somatostatin receptors constitute a 15 family of five different receptor subtypes (Bell and Reisine, Trends Neurosci., 16, 34-38, 1993), which may be distinguished on the basis of their tissue specificity and/or biological activity. 20 Therapeutic uses of somatostatin analogs By virtue of their inhibitory pharmacological properties, Somatostatin analogs can be used for the treatment of patients with hormone-secreting and hormone-dependent tumors. At the present, symptoms associated with metastatic Carcinoid 25 tumors (flushing, diarrhea, valvular heart disease and abdominal pain) and vasoactive intestinal peptide (VIP) secreting adenomas (watery diarrhea) are treated with Octreotide. Octreotide was also approved for the treatment of severe gastrointestinal hemorrhages and Acromegaly. In 30 addition, the abundance of high affinity Somatostatin receptors in various tumors enables the use of radio-labeled Somatostatin analogs in-vivo for visualization of these tumors (Lamberts et al. N. Engl. J. Med., 334:246 1996). In neuroendocrine tumors, particularly Carcinoids and 35 VIPomas, Octreotide inhibits both the secretion and the – 4 – WO99/65508 PCT/IL99/00329 effect of the active agent. Thus, in VIPomas characterized by profuse secretory diarrhea, Somatostatin analogs reduce the diarrhea through the inhibition of VIP secretion, and by direct effect on intestinal secretion. However, response to 5 the drug often decreases with time, possibly due to down-regulation of Somatostatin receptors on tumor cells or to the generation of receptor negative clone. The absence of consistent antiproliferative effect may be related to the poor affinity of Octreotide to some of the Somatostatin 10 receptor subtypes found in these tumors (Lamberts et al. ibid.). Native Somatostatin and Octreotide reportedly improve secretory diarrhea symptoms, other than those associated with neuroendocrine tumors. Control of secretory diarrhea 15 associated with short bowel syndrome, ileostomy diarrhea, idiopathic secretory diarrhea, diarrhea associated with amyloidosis, and diabetic diarrhea have been reported. Both compounds have also shown some promise in the management of refractory diarrhea related to AIDS, especially in patients 20 without identifiable pathogens. Somatostatin analogs known in the art may not provide sufficient selectivity or receptor subtype selectivity, particularly as anti-neoplastic agents (Reubi and Laissue, TIPS, 16, 110-115, 1995). 25 Somatostatin analogs selective to type 2 and 5 receptors which inhibit growth hormone but not insulin release may potentially be used for treatment of Non Insulin dependent Diabetes Mellitus (NIDDM). Lower potency on glucagon-release inhibition is preferred for reduction of peripheral 30 resistance to insulin and improvement of glycemic-control. Growth hormone is a direct antagonist of the insulin receptor in the periphery and growth hormone overproduction is associated with insulin peripheral resistance. Elevated IGF, 35 which is the principal biological signal of growth hormone, is associated with diabetic complications such as angiopathy, – 5 – WO99/65508 PCT/IL99/00329 retinopathy and nephropathy. Nephropathy is one of the major complications of diabetic angiopathy and one of the leading causes of end stage renal failure and death in diabetic patients. Evidence of the significant involvement of the 5 GH-IGF axis in diabetic and other nephropathies has been provided by several studies (Flyvbjerg A. Kidney Int. S12-S19, 1997). It was recently found that increased serum growth hormone levels in the Non-Obese-Diabetic (NOD) mice are similar to the changes described in humans (Landau et al. 10 J. Am. Soc. Nephrol. 8:A2990, 1997). These findings enable the elucidation of the role of the growth hormone-IGF axis in diabetic retinopathy and testing somatostatin analogs for potential therapeutic effect in these secondary diabetes-associated complications. 15 Improved Peptide Analogs It would be desirable to achieve peptide analogs with greater specificity to receptor subtypes thereby achieving enhanced clinical selectivity. 20 As a result of major advances in organic chemistry and in molecular biology, many bioactive peptides can now be prepared in quantities sufficient for pharmacological and clinical utilities. Thus in the last few years new methods have been established for the treatment and therapy of 25 illnesses in which peptides have been implicated. However, the use of peptides as drugs is limited by the following factors: a) their low metabolic stability towards proteolysis in the gastrointestinal tract and in serum; b) their poor absorption after oral ingestion, in particular due to their 30 relatively high molecular mass or the lack of specific transport systems or both; c) their rapid excretion through the liver and kidneys; and d) their undesired side effects in non-target organ systems, since peptide receptors can be widely distributed in an organism. 35 – 6 – WO99/65508 PCT/IL99/00329 It would be most beneficial to produce conformationally constrained peptide analogs overcoming the drawbacks of the native peptide molecules, thereby providing improved therapeutic properties. 5 A novel conceptual approach to the conformational constraint of peptides was introduced by Gilon, et al., (Bio-polvmers 31:745, 1991) who proposed backbone to backbone cyclization of peptides. The theoretical advantages of this strategy 10 include the ability to effect cyclization via the carbons or nitrogens of the peptide backbone without interfering with side chains that may be crucial for interaction with the specific receptor of a given peptide. While the concept was envisaged as being applicable to any linear peptide of 15 interest, in point of fact the limiting factor in the proposed scheme was the availability of suitable building units that must be used to replace the amino acids that are to be linked via bridging groups. The actual reduction to practice of this concept of backbone cyclization was 20 prevented by the inability to devise any practical method of preparing building units of amino acids other than glycine (Gilon et al., J. Org. Chem, 587:5687, 1992). Further disclosures by Gilon and coworkers (WO 95/33765 and 25 WO 97/09344)provided methods for producing building units required in the synthesis of backbone cyclized peptide analogs. Recently, The successful use of these methods to produce backbone cyclized peptide analogs having somatostatin activity was also disclosed (WO 98/04583). All of these 30 methods are incorporated herein in their entirety, by reference. None of the background art teaches or suggests the somatostatin analogs disclosed herein having improved 35 therapeutic selectivity. – 7 – WO99/65508 PCT/IL99/00329 SUMMARY OF THE INVENTION According to the present invention, novel peptide analogs 5 which are characterized in that they incorporate novel building units with bridging groups attached to the alpha nitrogens of alpha amino acids. Specifically, these compounds are backbone cyclized somatostatin analogs comprising a peptide sequence of four to twenty four amino 10 acids, each analog incorporating at least one building unit, said building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester or disulfide, wherein the at least one building unit is connected via said bridging group 15 to form a cyclic structure with a moiety selected from the group consisting of a second building unit, the side chain of an amino acid residue of the sequence or the N-terminal amino acid residue. Preferably, the peptide sequence incorporates 4 to 14 residues, more preferably 4 to 12 amino acids, most 20 preferably 5-9 amino acids. Heretofore conformationally constrained backbone cyclized somatostatin analogs had selectivity predominantly to receptor subtype 5. These analogs were of limited therapeutic 25 or diagnostic utility. According to the present invention it is now disclosed that preferred analogs are hexapeptide analogs with improved selectivity to the SST subtype 3 rather than subtype 5. Most 30 preferred analogs include novel octapeptide analogs of somatostatin which display receptor selectivity to SST subtypes 2 and 5. Additional more preferred somatostatin analogs may advantageously include bicyclic structures containing at least one cyclic structure connecting two 35 building units and a second cyclic structure which is – 8 – WO99/65508 PCT/IL99/00329 selected from the group consisting of side-chain to side-chain; backbone to backbone and backbone to end. Some of these bicyclic analogs display receptor selectivity to the SST subtype 2. 5 For certain hexapeptide preferred analogs of the present invention(denoted herein PTR numbers 3123, 3113 and 3171), the amino acid Asn was substituted by the backbone Phe building unit at position 5. The sterioisomer substitution of 10 the native L-Trp at position 8 to D-Trp was made to improve the stability of the analog. The Thr residue at position 10 was substituted by the corresponding backbone Phe building unit. The unique configuration substitution at position 9 from L-Lys to D-Lys as shown in PTRs 3123 and 3171 in 15 comparison to PTR 3113 imparts improved selectivity of binding to the SST receptor subtype SST-R3 rather than SST-R5. A currently most preferred analog of the present invention is 20 PTR 3173 having improved selectivity of binding to the SST receptor subtype SST-R2 and SST-R5. For additional most preferred analogs disclosed, the bridge is connected between Nc-w-functionalized derivative of an amino acid and the N-terminus of the peptide sequence. For 25 other preferred analogs of the present invention the bridge is connected between a building unit comprising an No-W functionalized derivative having a terminal thio group and another such derivative of an amino acid, or to the side chain of a Cys residue, to a mercapto-containing acid or to 30 any other SH containing moiety to form a disulfide bridge. For certain preferred analogs further substitutions of amino acids are disclosed. For example substitution of Phe residues with N-Methyl-Phe residues for increasing the 35 bio-availability of the compound and conjugation of mono- and – 9 – WO 99/65508 PCT/IL99/00329 di-saccharides moieties at the amino terminus for increasing oral bio-availability. The most preferred backbone cyclized somatostatin analogs 5 according to the invention are described in table 1: Table 1. The most preferred analogs of the invention. PTR Sequence SST-R 3171 Phe*-Phe-Phe-(D)Trp-(D)Lys-Phe(C2)-X 3113 Phe(C 1)-Phe-Phe-(D)Trp-Lys-Phe(N2)-X 3 3123 Phe(C 1)-Phe-Phe-(D)Trp-(D)Lys-Phe(N2)-X 3 3209 Phe(N2)-Tyr-(D)2Nal-Lys-Val-Gly(C2)-Thr-X 1 3183 Phe(N2)-Tyr-(D)Trp-Lys-Val-Gly(C2)-2Nal-X 5 3185 Phe(N2)-Tyr-(D)Trp-Lys-Val-Val-Gly(C2)-X 5 3201 Phe(N2)-Tyr-(D)Trp-Lys-Ser-2Nal-Gly(C2)-X 5 3203 Phe(N2)-Phe-(D)Trp-Lys-Thr-2Nal-Gly(C2)-X 3,5 3173 GABA*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X 2,5 3197 Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X 3 3205 Phe(C3)-Cys*-Phe-(D)Trp-Lys-Thr-Cys*-Phe-Phe(N3)-X 2 3207 (D)Phe-Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X 2,3 3229 Galactose-Dab*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X where X is -NH 2 or -OH and the bridging group extends between the two building units or as indicated below: 10 For PTR 3171 and PTR 3173, the asterisk denotes that the bridging group is connected between the Na-w-functionalized derivative of an amino acid and the N terminus of the peptide. For PTR 3197 and PTR 3207, the asterisk denotes that the bridging group is connected between the 15 Na-w-functionalized derivative of an amino acid and the side chain of the Cys residue. PTR 3205 is a bicyclic compound in which one bridge connects the two building units (Phe-C3 and Phe-N3) and the second is a disulfide bridge formed between the two Cys residues. 20 SST-R indicates the somatostatin receptor subtypes to which each analog is selective. – 10 – WO99/65508 PCT/IL99/00329 These backbone cyclized somatostatin peptide analogs are prepared by incorporating at least one No-a-functionalized derivative of an amino acids into a peptide sequence and 5 subsequently selectively cyclizing the functional group with one of the side chains of the amino acids in the peptide sequence or with another w-functionalized amino acid derivative. The Na-w-functionalized derivative of amino acids preferably have the following formula: 10 B-N-CH(R’) -CO-OH x 15 A–G Formula No. 1 20 wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R’ is an amino acid side chain, optionally bound with a specific protecting group; B is a protecting group selected from the group 25 consisting of alkyloxy, substituted alkyloxy, or aryl carbonyls; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, aldehydes, alcohols and alkyl halides; and A is a specific protecting group of G. 30 Preferred building units are the A -functionalized amino acid derivatives wherein X is alkylene; G is a thiol group, an amino group or a carboxyl group; and R’ is the side chain of an amino acid. Further preferred are w-functionalized amino acid derivatives wherein R’ is protected with a specific 35 protecting group. More preferred are e-functionalized amino acid derivatives wherein G is an amino group, a carboxyl group, or a thiol group of the following formulae: – 11 – WO 99/65508 PCT/IL99/00329 B-N-CH (R’) -CO-OH B-N-CH (R’) -CO-OH B-N-CH (R’) -CO-OH x x x 5 III HN- CO- and S Formula No. 2 Formula No. 3 Formula No. 4 10 wherein X, R’ and B are as defined above. The most striking advantages of these methods are: 1) cyclization of the peptide sequence is achieved without compromising any of the side chains of the peptide thereby 15 decreasing the chances of sacrificing functional groups essential for biological recognition and function. 2) optimization of the peptide conformation is achieved by allowing permutation of the bridge length, direction, and bond type (e.g., amide, disulfide, thioether, thioester, 20 etc.) and position of the bond in the ring. 3) when applied to cyclization of linear peptides of known activity, the bridge can be designed in such a way as to minimize interaction with the active region of the peptide and its cognate receptor. This decreases the chances of the 25 cyclization arm interfering with recognition and function, and also creates a site suitable for attachment of tags such as radioactive tracers, cytotoxic drugs, light capturing substances, or any other desired label. 30 Backbone cyclized analogs of the present invention may be used as pharmaceutical compositions and in methods for the treatment of disorders including: cancers (including carcinoid syndrome), endocrine disorders (including acromegaly and NIDDM), diabetic-associated complications 35 (including diabetic nephropathy, diabetic angiopathy and diabetic retinopathy), gastrointestinal disorders, pancreatitis, autoimmune diseases (including Rheumatoid Arthritis and psoriasis), atherosclerosis, restenosis, – 12 – WO99/65508 PCT/IL99/00329 post-surgical pain, and inflammatory diseases. In addition, somatostatin analogs according to the present invention will be useful in the prevention of atherosclerosis and restenosis by inhibition of growth factors involved in these disorders. 5 The preferred analogs disclosed in the present invention possess unique features of metabolic stability, selectivity in their in-vivo activities and safety. The most preferred analog disclosed (PTR 3173), offers a drug-candidate with a 10 clear therapeutic potential, for the treatment of Carcinoid tumors, Acromegaly and diabetic-associated complications. This most preferred analog has significant advantages over any other Somatostatin analog currently available, in that it is equipotent to available Somatostatin analogs in growth 15 hormone inhibition without appreciable effects on insulin or glucagon. The pharmaceutical compositions comprising pharmacologically active backbone cyclized somatostatin agonists or antagonists 20 and a pharmaceutically acceptable carrier or diluent represent another embodiment of the invention, as do the methods for the treatment of cancers, endocrine disorders, gastrointestinal disorders, diabetic-associated complications, pancreatitis, autoimmune diseases, and 25 inflammatory diseases, atherosclerosis and restenosis using such compositions. The pharmaceutical compositions according to the present invention advantageously comprise at least one backbone cyclized peptide analog which is selective for one or two somatostatin receptor subtypes. These pharmaceutical 30 compositions may be administered by any suitable route of administration, including orally, topically or systemically. Preferred modes of administration include but are not limited to parenteral routes such as intravenous and intramuscular injections, as well as via nasal or oral ingestion. 35 – 13 – WO99/65508 PCT/IL99/00329 Backbone cyclized analogs of the present invention may also be used as pharmaceutical compositions in methods for diagnosing cancer and imaging the existence of tumors or their metastases. The methods for diagnosis of cancer 5 comprise administering to a mammal including a human patient a backbone cyclic analog or analogs labeled with a detectable probe which is selected from the group consisting of a radioactive isotope and a non-radioactive tracer. The methods for the diagnosis or imaging of cancer using such 10 compositions represent another embodiment of the invention. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a graph showing the percent inhibition of 15 SRIF binding to the 5 human cloned somatostatin receptors by PTR-3173. Figure 2 is a graph showing the nonspecific binding of Somatostatin analogs (tested at a concentration of 100 nM) to 20 various G-protein coupled receptors. Figure 3 is a graph showing the effect of somatostatin analogs according to the present invention on the release of growth hormone compared to Octreotide. 25 Figure 4 is a graph showing the dose response effect of somatostatin analog according to the present invention on the release of glucagon. 30 Figures 5a and 5b are graphs showing the effect of somatostatin analogs according to the present invention on the release of insulin compared to Octreotide in three distinct experiments. 35 – 14 – WO99/65508 PCT/IL99/00329 DETAILED DESCRIPTION OF THE INVENTION The compounds herein described may have asymmetric centers. All chiral, diastereomeric, and racemic forms are included in 5 the present invention. Many geometric isomers of double bonds and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. 10 By “stable compound” or “stable structure” is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. 15 As used herein and in the claims, “alkyl” or “alkylenyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having one to ten carbon atoms; “alkenyl” is intended to include hydrocarbon chains of either a straight or branched configuration having 20 two to ten carbon atoms and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like; and “alkynyl” is intended to include hydrocarbon chains of either a straight or branched configuration having from two to ten 25 carbon atoms and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, and the like. As used herein and in the claims, “aryl” is intended to mean 30 any stable 5- to 7-membered monocyclic or bicyclic or 7-to 14-membered bicyclic or tricyclic carbon ring, any of which may be saturated, partially unsaturated or aromatic, for example, phenyl, naphthyl, indanyl, or tetrahydronaphthyl etc. 35 As used herein and in the claims, “alkyl halide” is intended – 15 – WO99/65508 PCT/IL99/00329 to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the one to ten carbon atoms, wherein 1 to 3 hydrogen atoms have been replaced by a halogen atom such as Cl, F, Br, and I. 5 As used herein and in the claims, the phrase “therapeutically effective amount” means that amount of novel backbone cyclized peptide analog or composition comprising same to administer to a host to achieve the desired results for the 10 indications described herein, such as but not limited to inflammatory diseases, cancer, endocrine disorders and gastrointestinal disorders. The term, “substituted” as used herein and in the claims, 15 means that any one or more hydrogen atoms on the designated atom is replaced with a selection from the indicated group, provided that the designated atom’s normal valency is not exceeded, and that the substitution results in a stable compound. 20 When any variable (for example R, X, Z, etc.) occurs more than one time in any constituent or in any Formula herein, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such 25 combinations result in stable compounds. As used herein “peptide” indicates a sequence of amino acids linked by peptide bonds. The somatostatin peptide analogs of this invention comprise a sequence of 4 to 24 amino acid 30 residues, preferably 4 to 14 residues, more preferably 4 to 12 amino acids, most preferably 5-9 amino acids each residue being characterized by having an amino and a carboxy terminus. 35 A “building unit” indicates an N’ derivatized a amino acid of – 16 – WO99/65508 PCT/IL99/00329 the general Formula No. 5: N-CH (R’) -CO 5 X 10 G Formula No. 5 15 wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R’ is an amino acid side chain, optionally bound with a specific protecting 20 group; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, and alkyl halides; which is incorporated into the peptide sequence and subsequently selectively cyclized via the functional group G with one of the side chains of the 25 amino acids in said peptide sequence or with another w-functionalized amino acid derivative. The methodology for producing the building units is described in international patent applications published as WO 95/33765 and WO 98/04583 and in US patents 5,770,687 and 5,883,293, 30 all of which are expressly incorporated herein by reference thereto as if set forth herein in their entirety. The building units are abbreviated by the three letter code of the corresponding modified amino acid followed by the type of reactive group (N for amine, C for carboxyl), and an 35 indication of the number of spacing methylene groups. For example, Gly-C2 describes a modified Gly residue with a carboxyl reactive group and a two carbon methylene spacer, and Phe-N3 designates a modified phenylalanine group with an amino reactive group and a three carbon methylene spacer. 40 In generic formulae the building units are abbreviated as R – 17 – WO99/65508 PCT/IL99/00329 with a superscript corresponding to the position in the sequence preceded by the letter N, as an indication that the backbone nitrogen at that position is the attachment point of the bridging group specified in said formulae. 5 As used herein “backbone cyclic peptide” denotes an analog of a linear peptide which contains at least one building unit that has been linked to form a bridge via the alpha nitrogen of the peptide backbone to another building unit, or to 10 another amino acid in the sequence. Certain abbreviations are used herein to describe this invention and the manner of making and using it. For instance, AcOH refers to acetic acid, Alloc refer to 15 allyloxycarbonyl, Boc refers to the t-butyloxycarbonyl radical, BOP refers to benzotriazol-l-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate, DCC refers to dicyclohexylcarbodiimide, DCM refers to Dichloromethane, DIEA refers to 20 diisopropyl-ethyl amine, DMF refers to dimethyl formamide, EDT refers to ethanedithiol, Fmoc refers to the fluorenylmethoxycarbonyl radical, GH refers to growth hormone, HBTU refers to l-hydroxybenztriazolyltetramethyl-uronium 25 hexafluorophosphate, HF refers to hydrofluoric acid, HOBT refers to l-hydroxybenzotriazole, HPLC refers to high pressure liquid chromatography, IGF refers to insulin growth factor, MS refers to mass spectrometry, NIDDM refers to Non Insulin dependent Diabetes Mellitus, NMM refers to 30 N-methylmorpholine, NMP refers to 1-methyl-2-pyrolidonone, PyBOP refers to Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate, PyBrOP refers to Bromo-tris pyrrolidino-phosphonium hexafluorophosphate, rt refers to 35 room temperature, SRIF refers to Somatotropin Release – 18 – WO99/65508 PCT/IL99/00329 Inhibitory Factor, TBTU refers to 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate, t-Bu refers to the tertiary butyl radical, TFA refers to trifluoroacetic acid, VIP refers to vasoactive 5 intestinal peptide. The amino acids used in this invention are those which are available commercially or are available by routine synthetic methods. Certain residues may require special methods for 10 incorporation into the peptide, and either sequential, divergent and convergent synthetic approaches to the peptide sequence are useful in this invention. Natural coded amino acids and their derivatives are represented by three-letter codes according to IUPAC conventions. When there is no 15 indication, the L isomer was used. The D isomers are indicated by “D” before the residue abbreviation. List of Non-coded amino acids: Abu refers to 2-aminobutyric acid, Aib refers to 2-amino-isobutyric acid, p-Ala refers to p-Alanine, ChxGly refers to cyclohexyl Glycine, Dab refers to 20 Di amino butyric acid, GABA refers to gamma amino butyric acid, Hcys refer to homocystein, (p-Cl)Phe refers to para chloro Phenylalanine, (p-NH2)Phe refers to para amino Phenylalanine, (p-F)Phe refers to para fluoro Phenylalanine, (p-NO 2 )Phe refers to para nitro Phenylalanine, INal refers to 25 1-naphthylalanine, 2Nal refers to 2-naphtylalanine, Nva refers to norvaline, Thi refers to thienylalanine. Conservative substitution of amino acids as known to those skilled in the art are within the scope of the present 30 invention. Conservative amino acid substitutions includes replacement of one amino acid with another having the same type of functional group or side chain e.g. aliphatic, aromatic, positively charged, negatively charged. These substitutions also include replacement of Phe residues with 35 N-Methyl-Phe residues for increasing the bio-availability of – 19 – WO99/65508 PCT/IL99/00329 the compound and conjugation of mono- and di-saccharides moieties at the amino terminus for increasing oral bio-availability (Nelson-Piercy et al. J. Clin. Endocrinol. And Metab. 78:329, 1994), or other such substitutions as may 5 enhance oral bioavailability, penetration into the central nervous system, targeting to specific cell populations and the like. Synthetic Approaches 10 According to the present invention peptide analogs are cyclized via bridging groups attached to the alpha nitrogens of amino acids that permit novel non-peptidic linkages. In general, the procedures utilized to construct such peptide analogs from their building units rely on the known 15 principles of peptide synthesis; most conveniently, the procedures can be performed according to the known principles of solid phase peptide synthesis. The innovation requires replacement of one or more of the amino acids in a peptide sequence by novel building units of the general Formula: 20 HN-CH(R)-COOH x X G 25 Formula No. 6 wherein R is the side chain of an amino acid, X is a spacer group and G is the functional end group by means of which 30 cyclization will be effected. The side chain R is the side chain of any natural or synthetic amino acid that is selected to be incorporated into the peptide sequence of choice. X is a spacer group that is selected to provide a greater or lesser degree of flexibility in order to achieve the 35 appropriate conformational constraints of the peptide analog. Such spacer groups include alkylene chains, substituted, branched and unsaturated alkylenes, arylenes, cycloalkylenes, and unsaturated and substituted cycloalkylenes. Furthermore, – 20 – WO99/65508 PCT/IL99/00329 X and R can be combined to form a heterocyclic structure. The terminal (w) functional groups to be used for cyclization of the peptide analog include but are not limited to: 5 a. Amines, for reaction with electrophiles such as activated carboxyl groups, aldehydes and ketones (with or without subsequent reduction), and alkyl or substituted alkyl halides. b. Alcohols, for reaction with electrophiles such as 10 activated carboxyl groups. c. Thiols, for the formation of disulfide bonds and reaction with electrophiles such as activated carboxyl groups, and alkyl or substituted alkyl halides. d. 1,2 and 1,3 Diols, for the formation of acetals and 15 ketals. e. Alkynes or Substituted Alkynes, for reaction with nucleophiles such as amines, thiols or carbanions; free radicals; electrophiles such as aldehydes and ketones, and alkyl or substituted alkyl halides; or organometallic 20 complexes. f. Carboxylic Acids and Esters, for reaction with nucleophiles (with or without prior activation), such as amines, alcohols, and thiols. g. Alkyl or Substituted Alkyl Halides or Esters, for 25 reaction with nucleophiles such as amines, alcohols, thiols, and carbanions (from active methylene groups such as acetoacetates or malonates); and formation of free radicals for subsequent reaction with alkenes or substituted alkenes, and alkynes or substituted alkynes. 30 h. Alkyl or Aryl Aldehydes and Ketones for reaction with nucleophiles such as amines (with or without subsequent reduction), carbanions (from active methylene groups such as acetoacetates or malonates), diols (for the formation of acetals and ketals). 35 i. Alkenes or Substituted Alkenes, for reaction with – 21 – WO99/65508 PCT/IL99/00329 nucleophiles such as amines, thiols, carbanions, free radicals, or organometallic complexes. j. Active Methylene Groups, such as malonate esters, acetoacetate esters, and others for reaction with 5 electrophiles such as aldehydes and ketones, alkyl or substituted alkyl halides. It will be appreciated that during synthesis of the peptide these reactive end groups, as well as any reactive side chains, must be protected by suitable protecting groups. 10 Suitable protecting groups for amines are alkyloxy, substituted alkyloxy, and aryloxy carbonyls including, but not limited to, tert butyloxycarbonyl (Boc), Fluorenylmethyloxycarbonyl (Fmoc), Allyloxycarbonyl (Alloc) and Benzyloxycarbonyl (Z). 15 Carboxylic end groups for cyclizations may be protected as their alkyl or substituted alkyl esters or thio esters or aryl or substituted aryl esters or thio esters. Examples include but are not limited to tertiary butyl ester, allyl ester, benzyl ester, 2-(trimethylsilyl)ethyl ester and 20 9-methyl fluorenyl. Thiol groups for cyclizations may be protected as their alkyl or substituted alkyl thio ethers or disulfides or aryl or substituted aryl thio ethers or disulfides. Examples of such groups include but are not limited to tertiary butyl, 25 trityl(triphenylmethyl), benzyl, 2-(trimethylsilyl)ethyl, pixyl(9-phenylxanthen-9-yl), acetamidomethyl, carboxymethyl, 2-thio-4-nitropyridyl. It will further be appreciated by the artisan that the various reactive moieties will be protected by different 30 protecting groups to allow their selective removal. Thus, a particular amino acid will be coupled to its neighbor in the peptide sequence when the Na is protected by, for instance, protecting group A. If an amine is to be used as an end group for cyclization in the reaction scheme the No will be 35 protected by protecting group B, or an c amino group of any – 22 – WO99/65508 PCT/IL99/00329 lysine in the sequence will be protected by protecting group C, and so on. The coupling of the amino acids to one another is performed as a series of reactions as is known in the art of peptide 5 synthesis. Novel building units of the invention, namely the Na-w functionalized amino acid derivatives are incorporated into the peptide sequence to replace one or more of the amino acids. If only one such Na-w functionalized amino acid derivative is selected, it will be cyclized to a side chain 10 of another amino acid in the sequence or to either of the two terminal amino acids of the peptide sequence. For instance: (a) an Na-(e-amino alkylene) amino acid can be linked to the carboxyl group of an aspartic or glutamic acid residue; (b) an No ‘ -(e-carboxylic alkylene) amino acid can be linked to 15 the s- amino group of a lysine residue; (c) an Na-(e-thio alkylene) amino acid can be linked to the thiol group of a cysteine residue; and so on. A more preferred embodiment of the invention incorporates two such Na-w-functionalized amino acid derivatives which may be linked to one another to form 20 N-backbone to N-backbone cyclic peptide analogs. Three or more such building units can be incorporated into a peptide sequence to create bicyclic peptide analogs as will be elaborated below. 25 Thus, peptide analogs can be constructed with two or more cyclizations, including N-backbone to N-backbone, as well as backbone to side-chain or any other peptide cyclization. As stated above, the procedures utilized to construct somatostatin analogs of the present invention from novel 30 building units generally rely on the known principles of peptide synthesis. However, it will be appreciated that accommodation of the procedures to the bulkier building units of the present invention may be required. Coupling of the amino acids in solid phase peptide chemistry can be achieved 35 by means of a coupling agent such as but not limited to – 23 – WO 99/65508 PCT/IL99/00329 dicyclohexycarbodiimide (DCC), bis(2-oxo-3-oxazolidinyl) phosphinic chloride (BOP-Cl), benzotriazolyl-N-oxytrisdimethyl-aminophosphonium hexafluoro phosphate (BOP), l-oxo-l-chlorophospholane (Cpt-Cl), 5 hydroxybenzotriazole (HOBT), or mixtures thereof. It has now been found that coupling of the subsequent amino acid to the bulky building units of the present invention may require the use of additional coupling reagents including, but not limited to: coupling reagents such as PyBOP 10 (Benzotriazole-l-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate), PyBrOP (Bromo-tris-pyrrolidino-phosphonium hexafluorophosphate), HBTU (2-(lH-Benzotriazole-l-yl)-1,1,3,3- tetramethyluronium hexafluoro-phosphate), TBTU 15 (2-(lH-Benzotriazole-l-yl)-l,l,3,3-tetramethyluronium tetrafluoroborate). Novel coupling chemistries may be used, such as pre-formed urethane-protected N-carboxy anhydrides (UNCA’S), pre-formed acyl halides most preferably acyl chlorides. 20 Advantageously, it is also possible to use in situ generated amino acid chlorides. The amino acid chlorides could be generated by utilizing reagents such as bis-(trichloromethyl)carbonate, commonly known as triphosgene, for example. 25 Such coupling may take place at room temperature and also at elevated temperatures, in solvents such as toluene, DCM (dichloromethane), DMF (dimethylformamide), DMA (dimethylacetamide), NMP (N-methyl pyrrolidinone), dioxane, 30 tetrahydrofuran, diglyme and 1,3 dichloropropane, or mixtures of the above. The preferred backbone cyclized somatostatin analogs of the present invention are now described. 35 – 24 – WO 99/65508 PCT/IL99/00329 One embodiment has the general formula: Q 5 R6 7 8 9 R10 R11 R12X Q- 5-R -R -R -R -R o-R -NR 12-X 5 CO- (CH 2 )r Formula No. 7 wherein n are 1 to 5; 10 X designates a terminal carboxy acid, amide or alcohol group; Q is hydrogen or a mono- or di- saccharide
R
5 is gamma amino butyric acid, diamino butyric acid, Gly, p-Ala, 5-amino pentanoic acid or amino hexanoic 15 acid; R is (D)- or (L)-Phe or Tyr; R is (D)- or (L)-Trp,(D)- or (L)-Phe, (D)- or (L)- lNal or (D)- or (L)- 2Nal, or Tyr; R is (D)- or (L)-Trp; 20 R 9 is (D)- or (L)-Lys;
R
10 is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe; Ru is (D)- or (L)-Phe,(D)- or (L)-Ala, Nle, or Cys;
R
1 2 is Gly, Val, Leu, (D)- or (L)-Phe or 1Nal or 2Nal; 25 A most preferred compound according to this embodiment is denoted PTR 3173 wherein the residues are as follows: Q is hydrogen;
R
s is GABA; 30 R is Phe;
R
7 is Trp; R is (D)Trp;
R
9 is Lys;
R
10 is Thr; 35 Ru is Phe;
R
12 is Gly; n is 3; and – 25 – WO 99/65508 PCT/IL99/00329 X is an amide. Another preferred compound according to this embodiment is denoted PTR 3229 wherein the residues are as follows: 5 Q is galactose;
R
5 is Dab; R is Phe;
R
7 is (L)-Trp; R is (D) Trp; 10 R 9 is Lys;
R
10 i is Thr;
R
n 11 is Phe; R is Gly; n is 3; and 15 X is amide. Another embodiment has the general formula: 20 NR -R7- (D) Trp-Lys-Rio-R-NR 2 -X
(CH
2 ) m-Y- (CH2)n Formula No. 8 25 wherein: m and n are 1 to 5 X designates a terminal carboxy acid, amide or alcohol group; R is(D)- or (L)-Phe, or (D)- or (L)-Ala;
R
7 is Tyr, (D)- or (L)- Ala, or (D)- or (L)- Phe; 30 R i0 is Thr, Val, Ser, or Cys; Ru is Val, (D)- or (L)-lNal, (D)- or (L)-2Nal , or (D) or (L)-Phe;
R
12 is Gly, (D)- or (L)-Ala, or (D) or (L)-Phe; and Y is amide, thioether, thioester or disulfide. 35 Preferably: R is(D)- or (L)-Phe;
R
7 is Tyr or Phe;
R
10 is Thr, Val or Ser; – 26
–
WO 99/65508 PCT/IL99/00329 R’ is Val, INal or 2Nal;
R
12 is Gly; and Y is amide. 5 Yet another embodiment has the general formula: NR 6-R -R -Lys-Ri– 1 R -R 12-X L (CH 2 )m-Y- (CH 2 ) n 10 Formula No. 9 wherein: m and n are 1 to 5 X designates a terminal carboxy acid, amide or alcohol 15 group;
R
6 is(D)- or (L)-Phe, or (D)- or (L)-Ala;
R
7 is Tyr or (D)- or (L)- Phe; R is (D)- or (L)- Trp, (D)- or (L)-1Nal or (D)- or (L) -2Nal; 20 R 10 is Thr, Val, Ser, or Cys; Ru is Gly or (D) or (L)-Phe; R is Thr, GABA, (D)- or (L)-lNal, (D)- or (L)- 2Nal, or (D) or (L)-Phe; and Y is amide, thioether, thioester or disulfide. 25 Preferably, R is(D)- or (L)-Phe;
R
7 is Tyr; R is (D)Trp, (D)lNal or (D)2Nal; R1 0 is Val; 30 R 1 is Gly; R is Thr, INal or 2Nal; and Y is amide. One more preferred embodiment has the following formula: 35 R4 _r5 R6 R7 R8 R9 R10 – R 11 R12_X R -NR-R-R -R-RR -R “-1-X (CH2)m-Y-( CH2)n _ 40 Formula No. 10 – 27 – WO 99/65508 PCT/IL99/00329 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; 5 R is absent or is a terminal group of one to four amino acids;
R
5 is INal, 2Nal, P-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe; R and R may be absent, or are independently Gly, Tyr, 10 (D)- or (L)-Ala, or (D)- or (L)-Phe;
R
8 is (D)- or (L)-Trp;
R
9 is (D)- or (L)-Lys;
R
10 is absent or is Gly, Abu, Cys, Thr, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe; 15 Ru is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe;
R
12 is absent or is Val, Thr, iNal or 2Nal; and Y is amide, thioether, thioester or disulfide. Preferably:
R
4 is absent; 20 R 5 is (D)- or (L)-Phe, or (D)- or (L)-Ala; R6 may be absent or (D)- or (L)-Phe, Ala or Tyr; R is (D)- or (L)-Phe, Ala or Tyr; R is absent or is Thr, Val or (D)- or (L)-Phe; R is (D)- or (L)-Ala, or (D)- or (L)-Phe; and 25 R 1 2 is absent. Another embodiment has the general formula:
NR
5
-R
6
-R
7
R
8 -R -R R 11 -X 30 L (C m- (CH2) C2n)n Formula No. 11 35 wherein: m and n are 1 to 5
R
5 is CL)- or (D)- Phe, Tyr or (D)- or CL)- Ala; R is CL)- or (D)- Phe, Tyr or (D)- or (L)- Ala; R is absent or is (L or D)- Phe, Tyr or (D or L)- Ala; – 28 – WO 99/65508 PCT/IL99/00329
R
8 is (D)- or (L)-Trp;
R
9 is (D)- or (L)-Lys;
R
10 i is absent or is Thr, Val, Cys or (D)- or (L)-Ala; R is (L) or (D)-Phe, Cys, or (D)- or (L)-Ala; 5 Y is amide, thioether, thioester or disulfide. Preferably: R is (D)- or (L)-Ala;
R
7 is absent or is (D)- or (L)-Phe;
R
10 is Thr; 10 Ru is Cys; and X is an alcohol group. Yet another embodiment has the general formula: 15
NR
6
-NR
7 -(D or L)Trp-(D or L)Lys-RI°-NRu-NR 12
(C
2 )y(CH 2 ) C2)n 20 Formula No. 12 wherein: the dotted line indicates that the bridge is connected to NR 6 or NR at one end and to NR 11 or NR 12 at the other 25 end; R is absent or is (D)- or (L)-Phe or Ala; R is (D)- or (L)-Phe, Ala or Tyr; R is Thr, Ala, Val or Cys; Ru is absent or is (D)- or (L)-Phe, Ala, or Cys; 30 R 12 is absent or is Thr or Thr reduced to an alcohol; and Y is amide, thioether, thioester or disulfide. Preferably, the bridge is connected to NR 6 and NR or to NR 6 and NR 12 with R 12 being Thr reduced to an alcohol. 35 Another preferred embodiment has the general formula: – 29 – WO 99/65508 PCT/IL99/00329 Cys-R -R – (D) Trp-Lys-Rio-R”-NR 12-X
(CH
2 ) m-Y- (CH 2 ) n 5 Formula No. 13 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol 10 group; R is (D)- or (L)-Phe or Tyr;
R
7 is (D)- or (L)-Trp,(D)- or (L)-Phe, (D)- or (L)- 1Nal or (D)- or (L)- 2Nal, or Tyr; R 1 0 is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or 15 (D)- or (L)-Phe; Ru is (D)- or (L)-Phe or (D)- or (L)-Ala; R is Gly, Val, or (D)- or (L)-Phe; and Y is thioether, thioester or disulfide. Preferably: 20 R 6 is Phe;
R
7 is Trp; R1 0 is Thr;
R
11 is Phe; R is Gly; and 25 Y is disulfide. Another preferred embodiment has the general formula: R -Cys-R 6-R7- (D) Trp-Lys-Rio-R -NR 12-X 30
(CH
2 )m-Y-
(CH
2 ) n Formula No. 14 35 wherein m and n are 1 to 5; – 30 – WO 99/65508 PCT/IL99/00329 X designates a terminal carboxy acid, amide or alcohol group;
R
4 is (D)- or (L)-Phe or Tyr;
R
6 is (D)- or (L)-Phe or Tyr; 5 R7 is (D)- or (L)-Trp,(D)- or (L)-Phe, (D)- or (L)- INal or (D)- or (L)- 2Nal, or Tyr; R1 is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe; R” is (D)- or (L)-Phe or (D)- or (L)-Ala; 10 R 12 is Gly, Val, or (D)- or (L)-Phe; and Y is thioether, thioester or disulfide. Preferably:
R
4 is (D)Phe; R is Phe; 15 R 7 is Trp;
R
10 is Thr; R 1 is Phe;
R
12 is Gly; and Y is disulfide. 20 Another more preferred embodiment has the general formula: 1 I NR -Cys-R – (D) Trp-Lys-Rio-Cys-R 12-NR -X 25 25
(CH
2 )m-Y-
(CH
2 )n Formula No. 15 30 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group;
R
5 is (D)- or (L)-Phe or (D)- or (L)-Ala; R is (D)- or (L)-Trp, (D)- or (L)-Phe, (D)- or (L)- iNal 35 or (D)- or (L)- 2Nal, or Tyr; – 31 – WO 99/65508 PCT/IL99/00329 R10 is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe;
R
12 is Gly, Val, or (D)- or (L)-Phe; R13 is (D)- or (L)-Phe or (D)- or (L)-Ala; and 5 Y is amide, thioether, thioester or disulfide. Preferably:
R
5 is Phe;
R
7 is Phe; R 10 is Thr; 10 R 12 is Gly, Val, or (D)- or (L)-Phe;
R
13 is Phe; and Y is amide. Additional preferred embodiments were synthesized using 15 multiple peptide parallel synthesis procedure. These comprise heptapeptide and octapeptide analogs in four groups (A-D) as described below. Group A: 20 R -NR 6-R 7- (D) Trp-Lys-Rio-NR I-R 12-X
(CH
2 )m-Y- (CH2) n Formula No. 16 25 wherein: m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group;
R
5 is absent or is 2Nal; 30 R is Phe or Gly;
R
7 is (p-Cl)Phe, (p-NH 2 )Phe, (p-F) Phe, (p-NO 2 )Phe or ChxGly;
R
1 0 is Val, Gly, or (D)ChxGly;
R
1 1 is Trp or Gly; 35 R 12 is 2Nal or Thr; Y is amide, thioether, thioester or disulfide. – 32 – WO 99/65508 PCT/IL99/00329 Group B: Phe(N2) -R 7 – (D) Trp-Lys-Val-R 1 — Gly(C2)-X
(CH
2 )m-Y- (CH 2 ) n 5 Formula No. 17 wherein: m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol 10 group; R is (p-Cl)Phe, (p-NH 2 )Phe, (p-NO 2 )Phe or Tyr; Ru is Ile, Val or Ala; Y is amide. 15 Group C: GABA-Phe-Trp- (D) Trp-Lys-R 1
°-R
11 -Gly(C3)-X
(CH
2 )m-Y- (CH 2 ) n 20 Formula No. 18 wherein: m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; 25 R1 0 is Ala, Abu, Nle, Val or Thr;
R
11 is Phe, Tyr, (p-Cl)Phe, (p-NH 2 )Phe, (p-NO 2 )Phe or (p-F)Phe; Y is amide, thioether or thioester. 30 Group D: p-Ala-R’-R -(D)Trp-Lys-Thr-R”-Gly(C3) – (D) Phe-X
(CH
2 )m-Y- (CH 2 )n 35 Formula No. 19 – 33 – WO 99/65508 PCT/IL99/00329 wherein: m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group;
R
6 is Val, Phe, (p-F) Phe or (p-Cl)Phe; 5 R 7 is Trp, Tyr, (p-Cl)Phe, (p-NH 2 )Phe, (p-F)Phe, (p-NO 2 ) Phe or ChxGly;
R
1 is Val or ChxGly; Y is amide. 10 The preferred analogs of the multiple parallel synthesis group are described in table 2 below: Table 2: Preferred multiple parallel synthesis sequences. Pep Position in SRIF sequence No. 5 6 7 8 9 10 11 12 13 5 Phe(N2) (p-NH 2 )Phe (D)Trp Lys Val Gly(C2) 2Nal A 6 Phe(N2) (p-CI)Phe (D)Trp Lys Val Gly(C2) 2Nal 7 Phe(N2) (p-F)Phe (D)Trp Lys Val Gly(C2) 2Nal 8 Phe(N2) (p-NO 2 )Phe (D)Trp Lys Val GIy(C2) 2Nal 35 Phe(N2) (p-Cl)Phe (D)Trp Lys Gly Trp(C3) Thr 72 2Nal GIv(N3) ChxGly (D)Trp Lys (D)ChxGly Gly(C2) Thr 22 Phe(N2) Tyr (D)Trp Lys Val lie Gly(C2) B 27 Phe(N2) (p-NH 2 )Phe (D)Trp Lys Val Val Gly(C2) 28 Phe(N2) (p-CI)Phe (D)Trp Lys Val Ala Gly(C2) 30 Phe(N2) (p-NO 2 )Phe (D)Trp Lys Val Val Gly(C2) 52 GABA Phe Trp (D)Trp Lys Ala Phe Gly(C3) C 53 GABA Phe Trp (D)Trp Lys Abu Phe Gly(C3) 56 GABA Phe Trp (D)Trp Lys Nle Phe Gly(C3) 58 GABA Phe Trp (D)Trp Lys Val Phe Gly(C3) 61 GABA Phe Trp (D)Trp Lys Thr Phe Gly(C3) 62 GABA Phe Trp (D)Trp Lys Thr (p-NH2)Phe Gly(C3) 63 GABA Phe Trp (D)Trp Lys Thr (p-C)Phe Gly(C3) 64 GABA Phe Trp (D)Trp Lys Thr (p-F)Phe Gly(C3) 65 GABA Phe Trp (D)Trp Lys Thr (p-NO2)Phe Gly(C3) 66 GABA Phe Trp (D)Trp Lys Thr Tyr Gly(C3) 83 B-Ala (p-C1)Phe Trp (D)Trp Lys Thr ChxGly GlyC3 (D)Phe D 84 5-Ala (p-F)Phe Trp (D)Trp Lys Thr ChxGly GlyC3 (D)Phe 88 p-Ala Val Trp (D)Trp Lys Thr ChxGly GIyC3 (D)Phe 89 O-Ala Phe Tyr (D)Trp Lys Thr Val GIyC3 (D)Phe 90 p3-Ala Phe (p-NO 2 )Phe (D)Trp Lys Thr Val GIyC3 (D)Phe 91 p-Ala Phe (p-CI)Phe (D)Trp Lys Thr Val GlyC3 (D)Phe 92 B-Ala Phe (p-F)Phe (D)Trp Lys Thr Val GlyC3 (D)Phe 93 p-Ala Phe (p-NH 2 )Phe (D)Trp Lys Thr Val GlyC3 (D)Phe 94 1-Ala Phe ChxGly (D)Trp Lys Thr Val GIyC3 (D)Phe – 34 .~inrTm mITFl HEET (RULE 26) WO99/65508 PCT/IL99/00329 The most preferred backbone cyclized somatostatin analogs according the present invention are described in table 3: 5 Table 3: The most preferred analogs. PTR Sequence 3171 Phe*-Phe-Phe-(D)Trp-(D)Lys-Phe(C2)-X 3113 Phe(C1)-Phe-Phe-(D)Trp-Lys-Phe(N2)-X 3123 Phe(C1)-Phe-Phe-(D)Trp-(D)Lys-Phe(N2)-X 3209 Phe(N2)-Tyr-(D)2Nal-Lys-Val-Gly(C2)-Thr-X 3183 Phe(N2)-Tyr-(D)Trp-Lys-Val-Gly(C2)-2Nal-X 3185 Phe(N2)-Tyr-(D)Trp-Lys-Val-Val-Gly(C2)-X 3201 Phe(N2)-Tyr-(D)Trp-Lys-Ser-2Nal-Gly(C2)-X 3203 Phe(N2)-Phe-(D)Trp-Lys-Thr-2Nal-Gly(C2)-X 3173 GABA*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X 3197 Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X 3205 Phe(C3)-Cys*-Phe-(D)Trp-Lys-Thr-Cys*-Phe-Phe(N3)-X 3207 (D)Phe-Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X 3229 Galactose-Dab*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X where X is -NH 2 or -OH and the bridging group extends between the two building units or as indicated below: For PTR 3171 and PTR 3173, the asterisk denotes that the 10 bridging group is connected between the Na-,-functionalized derivative of an amino acid and the N terminus of the peptide. For PTR 3197 and PTR 3207, the asterisk denotes that the bridging group is connected between the N a–functionalized derivative of an amino acid and the side 15 chain of the Cys residue. PTR 3205 is a bicyclic compound in which one bridge connects the two building units (Phe-C3 and Phe-N3) and the second is a disulfide bridge formed between the two Cys residues. 20 Somatostatin is a tetradecapeptide hormone whose numerous regulatory functions are mediated by a family of five – 35 – WO99/65508 PCT/IL99/00329 receptors, whose expression is tissue dependent. Receptor specific analogs of somatostatin are believed to be valuable therapeutic agents in the treatment of various diseases. Attempts to design small peptide analogs having this 5 selectivity have not been highly successful. It has now unexpectedly been found that the conformationally constrained backbone cyclized somatostatin analogs of the present invention, are highly selective to SST receptor subtypes. 10 The backbone cyclic peptides of this invention are novel selective analogs and preferably bind with higher affinity to a single receptor of the somatostatin receptor family. PTR 3113 and PTR 3123 are selective for the type 3 somatostatin receptor previously studied analogs have failed to achieve 15 specificity to this receptor subtype. PTR 3183,3185 and 3201 are selective for the type 5 somatostatin receptor. PTR 3209 is selective for the type 1 receptor. PTR 3203 is selective for receptors 3 and 5, and PTR 3173 is selective for receptors 2 and 5. PTR 3205 is a bicyclic analog which is 20 selective to somatostatin receptor type 2. The amino acid sequence of the corresponding backbone hexacyclic analogs (PTRs 3113, 3123 and 3171)is based on what are believed to be the most important amino acids derived 25 from the native SRIF-14. From the data in the literature (Bauer, et al. Life Sciences, 31:1133, 1982), it was concluded that the amino acids of the native SRIF-14 in at 7 8 9 least positions 7 through 10, namely Phe , Trp , Lys , and Thr
°
, and preferably positions 6 through 10, namely Phe 6 , 30 Phe 7 , Trp 8 , Lys 9 , and Thr , are essential to the pharmacophore of the hormone. The present innovative backbone analogs preferably include 5 to 8 amino acids with special amine acid modifications. 35 For certain preferred analogs, the amino acid Asn was – 36 – WO99/65508 PCT/IL99/00329 substituted by the backbone Phe building unit at position 5. The configuration substitution of the native L-Trp at position 8 to D-Trp was made to improve the stability of the analog. The Thr residue at position 10 was deleted and the 5 sequence completed by the corresponding backbone Phe building unit. The unique configuration substitution at position 9 from L-Lys to D-Lys as shown in PTRs 3123 and 3171 in comparison to PTR 3113 imparts improved selectivity of binding to the SST receptor subtype SST-R3 rather than 10 SST-R5. In additional more preferred analogs further modification of amino acids were performed. For example substitution of Phe residues with Tyr for facilitating Iodination. Substitution 15 of Phe residues with N-Methyl-Phe residue (for example substitution of Phe 6 in PTR 3173 to yield PTR 3223 and substitution of Phe 6 and Phe 1 in PTR 3173 to yield PTR 3225) for increasing the bio-availability of the compound. Addition of mono- and di-saccharides moieties at the amino 20 terminus of certain compounds is performed for increasing the oral bio-availability (Nelson-Piercy et al. ibid.). For example galactose was conjugated to the N-terminal of compound similar to PTR 3173 to yield an analog having the sequence: 25 Galactose-Dab-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-NH 2 denoted herein PTR 3229. In certain most preferred analogs (PTR 3171 and 3173 for example) the bridge is connected between Na-a-functionalized 30 derivative of an amino acid and the N-terminus of the peptide sequence. For other preferred analogs of the present invention the bridge is connected between a building unit comprising an N -m functionalized derivative having a terminal thio group and another such derivative of an amino 35 acid, or to the side chain of a Cys residue, to a – 37 – WO99/65508 PCT/IL99/00329 mercapto-containing acid or to any other SH containing moiety to form a disulfide bridge. The present novel analogs provide an additional dimension to 5 the novelty of the backbone cyclization technology, in the utilization of a shortened backbone bridge (i.e., only one to three methylenes beside the peptide bond). This approach enables one to obtain much greater rigidity of the peptide, and to further constrain the desired conformation of the 10 native pharmacophore. An additional advantage of the hexapeptide analogs of the present invention is related to their relative low molecular weight (their sequence consisting of only six amino acids), 15 up to only 1000 daltons, in comparison to the most common somatostatin synthetic analogs which usually are hepta or octapeptides. Backbone cyclic somatostatin analogs of the present invention 20 (for example PTR 3123, 3173, 3201 and 3205) were found to possess considerable metabolic bio-stability against degradation by enzymes. This attribute could suggest a potentially long duration of activity in the body. The stability of the backbone cyclic analogs was comparable 25 to that of the metabolically stable drug Octreotide using experimental stability measurements based on degradation by various enzyme mixtures (e.g. renal homogenate, rat liver homogenate and human serum). All tested compounds showed significantly higher bio-stability than the native hormone 30 SRIF-14. In some of the corresponding non-cyclized peptides, some degradation was observed two hours after incubation, which indicated that the cyclization remarkably contributed to the stability of the peptide. The incorporation of the N-alkylated amino acids used for the backbone cyclization was 35 expected to confer metabolic bio-stability to these peptides. – 38 – WO99/65508 PCT/IL99/00329 Backbone cyclic analogs of the present invention bind in-vitro with high affinity to a defined subset of the human somatostatin receptors. This receptor selectivity indicates 5 its potential physiological selectivity in-vivo. Consistent with the in-vitro receptor binding, backbone cyclic analogs of the present invention selectively affects a defined system in the body while not affecting other known 10 physiological activities of the native hormone somatostatin. For example, PTR 3173 exerts significant inhibition with prolonged duration of action on the Growth Hormone-IGF-1 axis of a similar magnitude as the drug Octreotide, but it lacks the disadvantages of Octreotide such as inhibition of Insulin 15 secretion. PTR 3173 also has a considerably lower affect on the release of glucagon than Octreotide, it thus has the advantage of not causing hyperglycemia which makes it a very attractive compound for the treatment of Diabetes Type 2 (NIDDM). 20 As summarized in table 4 PTR 3173 possesses significant physiological selectivity over the drug Octreotide. PTR 3173 is a potent inhibitor of growth hormone but has much less activity on glucagon, and no considerable effect on insulin. 25 Table 4: Physiological Selectivity of PTR 3173 in comparison to Octreotide. GH iUDbU Glucagon Insulin GH / GH Analog pg/kg ID50 pg/kg ID50 pg/kg Insulin Glucagon Octreotide 0.08 0.65 26 309 8 PTR 3173 0.1 >100 >1000 >10000 >1,000 – 39 – WO99/65508 PCT/IL99/00329 PTRs 3123 inhibits only the release of glucagon secretion but not growth hormone or insulin which makes it a potential therapeutic agent for glucagonoma with no adverse effects on the release of growth hormone and insulin. In addition, it is 5 an anticancer candidate for malignancies expressing SST-R3 only. The native hormone SRIF as well as its synthetic analog Octreotide, inhibit simultaneously growth hormone, glucagon and insulin and therefore they are not selective. 10 PTR 3205 is a bicyclic compound in which one bridge connects the two building units and the second is a disulfide bridge formed between two Cys residues. This analog is selective for somatostatin receptor 2 and thus it is an anticancer candidate for imaging and treating malignancies expressing 15 this receptor subtype without influencing other somatostatin receptor activities. Similarly, analogs such as PTR 3201 are selective to somatostatin receptor 5 and are thus candidates for imaging the therapy of malignancies expressing this receptor subtype. 20 PTR 3173 shows a significant growth inhibition of CHO-cells expressing cloned human SST-R5, indicating a potential role in the treatment of SST-R5 expressing tumors (e.g. carcinoids, pituitary tumors). This analog also inhibits 25 Chromogranin A release from the human Carcinoid cell line, indicating an anti-tumor effect (example 5). The unique pharmacokinetic profile of PTR 3173 as evaluated in animals is consistent with its metabolic bio-stability as 30 evaluated in-vitro. This backbone cyclic somatostatin analog displays flip flop (a slow release kinetic) pharmacokinetics. Following subcutaneous administration, the apparent circulatory half life resulting from its rate of absorption but not from its rate of elimination. Following 35 subcutaneous administration to rats, PTR 3173 had a – 40 – WO 99/65508 PCT/IL99/00329 circulatory half-life of about 3 hours. This activity significantly exceeds that of the long acting drug Octreotide, which has a circulation half-life of only 40 minutes. The main pharmacokinetic parameters of PTR 3173 vs. 5 Octreotide are summarised in table 5. Table 5: Main pharmacokinetic parameters of PTR 3173 vs. Octreotide following IV & SC administration to Conscious Wistar rats. Route Drug F(%) Vss – E % Clearance (ml/kg) (i (ml/min/kg) …… …… . . ……… .. ……. …. …………. . …………. …. . . .. . …….. …. .i ……………….. ………….. …… iiiii il … …………. ………. …. … . ……….. ……. ……. .. . .. PTR 3173 – 653 31 10.3 13.0 IV ……………….. i.- – e ~ ……- –.. … ……. ………………………. .. …….. .. . ……………. ….. ………… ….. !!T :; … ………. …………. T ………….. …… … T ………………….. … . .. Octreotide* – 602 49 21.3 17.6 …… …. …. …….. . …….. –…….. . .. T ………. …….. ……….. …………. ……. ……………. ………….. …. …………….. .. .!i iii:i … . ……. ………….. 5 9 …………….. ………………… .T ……… …….. ……. ……. PTR 3173 99.6 – 170 15.9 13.3 SC Octreotide* 103 4023.0 17.1 ………. d e * ….. – . _ _ – -…………. … ………………………….. … ……………. : ………. …………… ……………. 13 i ……….. .. ……… … …….. ………… …. = : : :. .: :…. .. ………….. … ………. …………. ………. .. ……… . . …. 30. 10 * From Sandostatin (Octreotide acetate), Overview and clinical summary. Sandoz Pharmaceutical Corporation, 1992. F- Bioavailability, Vs. – Volume of distribution, T1/2- circulating half life, E – Extracted in urine 15 The backbone cyclic somatostatin analog PTR 3173 is selective to somatostatin receptors and binds significantly less other G-protein coupled receptors than Octreotide as found by screening both analogs and SRIF for binding to several such 20 receptors (example 6). This characteristic is of great advantageous because binding to non-somatostatin receptors could cause potential adverse effects in the body. PTR 3173 was furthermore found to be not mitogenic for human 25 lymphocytes in human peripheral blood lymphocytes (PBL) proliferation assays. PTR 3113 and PTR 3123 were found to be safe when administered intravenously to rats in a single dose of 6 mg/kg. 30 PTR 3173 was tested in various species for its initial – 41 – WO99/65508 PCT/IL99/00329 safety properties. Under the European Pharmacopoeia requirements for safety testing, it was declared a safe drug candidate at this stage of development. No toxicity signs in rodents or in dogs were seen when injected at a dose 5 10,000-fold higher then the efficacious dose for inhibiting Growth hormone release. General method for synthesis, purification and characterization of backbone cyclic peptides 10 Synthesis: Resin: ig Rink amide or Tenta-gel resin, with loading of 0.2-0.7 mmol/gr. Fmoc- deprotection: With 7 mL of 20% piperidine in NMP. Twice for 15 minutes following 5 washes with 10 ml NMP for 2 15 minutes with shaking. Couplings: 1. Regular couplings (coupling to simple amino acids): with a solution containing 3 equivalents amino acid, 3 equivalents PyBroP and 6 equivalents of DIEA in 7ml NMP. For 0.5-2 hours 20 with shaking. Coupling is monitored by ninhydrine test and repeated until the ninhydrine solution become yellow. 2. Coupling of His and Asn with a solution containing 5 equivalents DIC and 5 equivalents HOBT in 10 ml DMF. 3. Coupling to Gly building units: with a solution containing 25 3 equivalents amino acid, 3 equivalents PyBroP and 6 equivalents DIEA in 7ml NMP. Twice for 1-4 hours with shaking. 4. Coupling to building units which are not Gly: with a solution containing 5 equivalents amino acid, 1.5 equivalents 30 triphosgen and 13 equivalents collidine in 15ml dioxane or THF. Twice for 0.5-2 hours at 50 0 C with shaking. Removal of the Allyl and Alloc protecting groups of the building units: with 1.5 equivalents per peptide of Pd(PPh3)4 in 30 ml DCM containing 5% acetic acid and 2.5% NMM. For 1-4 35 hours with shaking. – 42 – WO99/65508 PCT/IL99/00329 Cyclization: with a solution containing 3 equivalents PyBOP and 6 equivalents DIEA in 7ml NMP. For 0.5-2 hours with shaking. Cyclization is monitored by ninhydrine test and repeated if necessary. 5 Cleavage: with 82%-95% TFA supplemented with scavengers: 1-15% H 2 0, 1-5% TIS and 1-5% EDT. Purification: An individual purification method for each backbone cyclic peptide is developed on analytical HPLC to give the maximum 10 isolation of the cyclic peptide from other crude components. The analytical method is usually performed using a C-18 Vydac column 250X4.6mm as the stationary phase and water/ACN containing 0.1%TFA mixture gradient. The preparative method is designed by implying the analytical 15 separation method on the 2″ C-18 Vydac preparative method. During the purification process, the peak containing the cyclic peptide is collected using a semi-automated fraction collector. The collected fractions are injected to the analytical HPLC for purity check. The pure fractions are 20 combined and lyophilized. Characterization: The combined pure lyophilized material is analyzed for purity by HPLC, MS and capillary electrophoresis and by amino acid analysis for peptide content and amino acid ratio 25 determination. General screening of somatostatin analogs. The backbone cyclic somatostatin analogs are screened by testing them in-vitro for their inhibition of the natural 30 peptide (SRIF-14) binding to its G-protein coupled receptors (example 3). Analogs which bind with high affinity are then tested for their influence on second messengers such as cyclic adenosine monophosphate (cAMP) levels, tyrosine phosphatase activity, growth hormone and chromogranin A 35 secretion, and on cell growth. Active analogs are furthermore tested in-vivo for inhibition – 43 – WO99/65508 PCT/IL99/00329 of hormones and enzyme secretion particular relevant model systems based on literature data indicating that SST-R2 and SST-R5 mediate most endocrine effects of Somatostatin, are inhibition of growth-hormone release, and amylase, gastric 5 acid, insulin and glucagon secretion which are based on the known endocrine activities of the native hormone SRIF and the somatostatin analog, Octreotide. The most preferred backbone cyclic somatostatin analogs: PTR-3201, PTR-3205 and PTR-3173, which possess receptor 10 specificity to SST-R5, SST-R2 and SST-R2 + SST-R5 respectively, were used to elucidate the physiological role of each somatostatin receptor on the endocrine profiles in addition to finding their potentials as drug candidates. 15 Conformationally constrained somatostatin analogs constructed based in part on the sequences of a number of known biologically active peptides or based on previously unknown novel sequences are presented in the examples below. The 20 following examples are intended to illustrate how to make and use the compounds and methods of this invention and are in no way to be construed as a limitation. 25 EXAMPLES Example 1. Detailed synthesis of PTR 3173. Five grams of Rink amide resin (NOVA) (0.56 mmol/g), were swelled in N-methylpyrrolidone (NMP) in a reaction vessel 30 equipped with a sintered glass bottom and placed on a shaker. The Fmoc protecting group was removed from the resin by reaction with 20% piperidine in NMP (2 times 10 minutes, 25 ml each). Fmoc removal was monitored by ultraviolet absorption measurement at 290 nm. A coupling cycle was 35 carried out with Fmoc-Gly-C3(Allyl) (3 equivalents) PyBrop (3 – 44 – WO99/65508 PCT/IL99/00329 equivalents) DIEA (6 equivalents) in NMP (20 ml) for 1 hour at room temperature. Reaction completion was monitored by the qualitative ninhydrin test (Kaiser test). Following coupling, the peptide-resin was washed with NMP (7 times with 25 ml 5 NMP, 2 minutes each). Capping was carried out by reaction of the peptide-resin with acetic anhydride (capping mixture: HOBt 400 mg, NMP 20 ml, acetic anhydride 10 ml, DIEA 4.4 ml) for 0.5 hours at room temperature. After capping, NMP washes were carried out as above (7 times, 2 minutes each). Fmoc 10 removal was carried out as above. Fmoc-Phe-OH was coupled in the same manner, and the Fmoc group removed, as above. The peptide resin was reacted with Fmoc-Thr(OtBu)-OH: coupling conditions were as above. Fmoc removal was carried out as above. Fmoc-Lys(Boc)-OH was coupled to the peptide resin by 15 the same coupling conditions. Coupling completion was monitored by the Fmoc test (a sample of the peptide resin was taken and weighed, the Fmoc was removed as above, and the ultraviolet absorption was measured). Fmoc-D-Trp-OH was coupled to the peptide resin with PyBrop, as described above. 20 Following Fmoc removal, Fmoc-Trp-OH was coupled in the same way. Following Fmoc removal, Fmoc-Phe-OH was coupled in the same manner. Following Fmoc removal, Fmoc-GABA-OH was coupled in the same way. The Allyl protecting group was removed by reaction with Pd(PPh 3
)
4 and acetic acid 5%, morpholine 2.5% 25 in chloroform, under argon, for 2 hours at room temperature. The peptide resin was washed with NMP as above. The Fmoc protecting group was removed from the peptide by reaction with 20% piperidine in NMP (2 times 10 minutes, 25 ml each). Cyclization was carried out with PyBOP 3 equivalents, DIEA 6 30 equivalents, in NMP, at room temperature for 2h. The peptide resin was washed and dried. The peptide was cleaved from the resin by reaction with TFA 94%, water 2.5%, EDT 2.5%, TIS (tri-isopropyl-silane) 1%, at 0 0 C for 15 minutes and 2 hours at room temperature under argon. The mixture was filtered 35 into cold ether (30 ml, 0 0 C) and the resin was washed with a – 45 – WO99/65508 PCT/IL99/00329 small volume of TFA. The filtrate was placed in a rotary evaporator and all the volatile components were removed. An oily product was obtained. It was triturated with ether and the ether decanted, three times. A white powder was obtained. 5 This crude product was dried. The weight of the crude product was 4 g. After purification by HPLC a single peak was obtained with 100% purity as detected by analytical HPLC and capillary electrophoresis. The expected mass of 1123 daltons was 10 detected by mass spectroscopy. Example 2: Detailed procedure of PTR 3205 synthesis by the triphosgen method. Two grams of Rink Amide (MBHA resin, NOVA, 0.46 mmol/gr) were 15 swelled over night in NMP in a reactor equipped with a sintered glass bottom, attached to a shaker. Fmoc was removed from the resin using 25% Piperidine in NMP (16 ml) twice for 15 min. After careful wash, seven times with NMP (10-15 ml), for 2 min each, coupling of Phe-N3 was accomplished using 20 Fmoc-Phe-N3-OH (3 eq, 2.76 mmol, 1.46 g’) dissolved in NMP (16 ml) and activated with PyBroP (2.76 mmol, 1.28 g’) and DIEA (6eq, 5.52 mmol, 0.95 ml) for 4 min at room temperature and then transferred to the reactor for coupling for 1h at room temperature. Following coupling the peptide-resin was 25 washed with NMP (10-15 ml) seven times for 2 min each. Reaction completion was monitored by qualitative Ninhydrine test (Kaiser test). Fmoc removal and wash was carried out as described above followed by wash with THF (10-15 ml) three times for 2 min each and Fmoc-Cys(Acm)-OH (5 eq, 4.6 mmol, 30 1.9 g’) was coupled to the BU-peptidyl-resin using bis-(trichloromethyl)carbonate (1.65 eq, 1.518 mmol, 0.45 g’) and collidine (14 eq, 12.88 mmol, 1.7 ml) in THF (30-35 ml, to give 0.14 M mixture) at 50 0 C for lh. and this coupling procedure was repeated. Assembly of Thr, Lys, (D)Trp, Phe, 35 Cys and PheC3 was accomplished by coupling cycles (monitored – 46 – WO99/65508 PCT/IL99/00329 by qualitative Ninhydrine test) using Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-(D)Trp(Boc)-OH, Fmoc-Phe-OH, Fmoc-Cys(Acm)-OH and Fmoc-PheC3-OH respectively, in each coupling cycle the amino acid was dissolved in NMP and was 5 activated with PyBroP and DIEA, following coupling the peptide-resin was washed than Fmoc removed followed by extensive wash with NMP, as described above for the first coupling. At the end of the assembly the peptidyl-resin underwent allyl/alloc deprotection under the following 10 conditions: the peptidyl resin was washed with DCM (10-15 ml) three times for 2 min each and with a mixture of DCM-AcOH-NMM (92.5%, 5%, 2.5% respectively) three times for 2 min each. 3 g’ of Pd(P(Ph) 3
)
4 were dissolved in the above mixture (80 ml) and the yellow suspension obtained was transferred to the 15 reactor and the mixture with the peptidyl-resin underwent degassing (by babbling Argon through the reactor’s sintered glass bottom) and then vigorously shacked for 2h. in the dark. The peptidyl-resin washed with DCM, CHC13 and NMP (a total of 15 washes 2 min each). Cyclization using PyBOP (3eq, 20 2.76 mmol, 1.436 g’) and DIEA (6eq, 5.52 mmol, 0.95 ml) in NMP (20 ml) at rt. for lh. and then second cyclization over night (under same conditions) took place. The peptidyl resin was washed with NMP followed by wash with DMF-water (15 ml, 4:1) three times for 2 min. each. I2 solution (5 eq, 4.6 25 mmol, 1.16 g’) in DMF-water (23 ml, 4:1) was added to the peptidyl-resin which was shacked at rt. for 40 min. to afford Cys-Cys cyclization. The peptidyl resin was filtered and washed extensively with DMF/water, DMF, NMP, DCM, CHCl 3 and also with 2% ascorbic acid in DMF. After final Fmoc 30 deprotection and wash as above and also wash with MeOH, followed by drying the peptidyl resin under vacuum for 20 min. the peptide was cleaved from the resin using 95% TFA, 2.5% TIS and 2.5% water in a total of 30 ml cocktail mixture for 30 min. at 00C under Argon and then l.5h. at rt. The 35 solution was filtered through extract filter into – 47 – WO99/65508 PCT/IL99/00329 polypropylene tube, the resin was washed with 5-6 ml cocktail and 4-5 ml TFA, the solution was evaporated by N 2 stream to give oily residue which on treatment with cold Et 2 0 solidify. Centrifugation and decantation of the Et 2 0 layer and 5 treatment with additional portion of cold Et 2 0 followed by centrifugation and decantation and drying the white solid under vacuum over night gave crude PTR-3205-02 (0.388 g’, 30%). 10 Example 3: Resistance to biodegradation. The in-vitro biostability of SST cyclic peptide analogs; PTRs 3113, 3123, and 3171, was measured in renal homogenate, and were compared to Octreotide (SandostatinTM), and to native somatostatin (SRIF-14). The results are shown in the Table 6 15 below. In this assay, the backbone cyclic peptide analogs of the present invention were as stable as Octreotide, and were much more stable than SRIF. The assay was based on HPLC determination of peptide degradation as a function of time in renal homogenate at 370C. 20 Table 6: Percent of intact molecule after incubation in renal homogenate. Time (hrs) SRIF Octreotide PTR-3113 PTR-3123 PTR-3171 PTR-3173 0 100 100 100 100 100 100 1 5 100 100 100 100 100 3 0 100 100 100 100 100 24 0 100 100 100 100 100 25 Example 4: Binding of analogs to somatostatin receptors. The somatostatin analogs were tested for their potency in inhibition of the binding of 125I-Tyri-SRIF (based on the method described by Raynor et. al., Molecular Pharmacology 43: 838, 1993) to membrane preparations expressing the – 48 – WO99/65508 PCT/IL99/00329 transmembranal somatostatin receptors (SST-R1,2,3,4 or 5). The receptor preparations used for these tests were either from the cloned human receptors selectively and stably expressed in Chinese Hamster Ovary (CHO) cells or from cell 5 lines naturally expressing the SST-Rs. Typically, cell membranes were homogenated in Tris buffer in the presence of protease inhibitors and incubated for 30-40 minutes with 12I-Tyr -SRIF with different concentrations of the tested sample. The binding reactions were filtered, the filters 10 were washed and the bound radioactivity was counted in gamma counter. Non specific binding was defined as the radioactivity remaining bound in the presence of 1 pM unlabeled SRIF-14. In order to validate positive signals of the binding tests, 15 and to eliminate non-specific signals, samples of irrelevant peptides, such as GnRH, that were synthesized and handled using the same procedures, were tested in the same assays as negative control samples. These samples had no binding activity in any of the assays. Results are shown in tables 7, 20 8 and 9 below and in figure 1. Table 7: Percent inhibition of SRIF-14 binding to cloned human somatostatin receptors 3 and 5 by backbone cyclic analogs. SST-R3 SST-R5 Concentration 10″ M 10 M 10 M 10″ M 10″ M 10 M PTR-3113 16 65 94 0 50 86 PTR-3123 24 41 84 0 0 0 PTR-3171 12 40 87 18 10 60 Total counts 12000 CPM 3600 CPM Non-specific 1200 CPM 900 CPM binding blank 400 CPM 400 CPM 25 – 49 – WO99/65508 PCT/IL99/00329 Table 8: Percent inhibition of SRIF-14 binding to cloned human somatostatin receptors by PTR 3173. Receptor Concentration (M) Subtype 10″11 10-1o 10″9 10- ” 10″ 10 SST-R1 0 0 0 0 5 15 SST-R2 15 30 42 80 95 96 SST-R3 2 1 1 4 50 89 SST-R4 0 0 0 0 5 5 SST-R5 20 48 63 82 95 95 5 Table 9: Concentration (nM) of somatostatin analogs to inhibit SRIF binding to each human cloned somatostatin receptors by 50%. PTR IC 50 (nM) SST-R1 SST-R2 SST-R3 SST-R5 3201 >10 1 10 10 ” 3203 >10 10 10 10 3197 10 ” 10 10 10 3205 >10 10 >10 >10 3207 10 10 10 10 3173 >10 10 10 – 10 10 Example 5. In-vitro bio-response of preferred backbone cyclic somatostatin analogs. A. Inhibition of cAMP in human Carcinoid BON-1 cells by the backbone cyclic somatostatin analog PTR 3173: 15 The activation of SST-R5 leads to the reduction of Adenylate Cyclase activity. Somatostatin receptors including type-5 receptors are expressed in the human Carcinoid derived cell line BON-1. This human cell culture served as an in-vitro discovery assay for novel Carcinoid therapeutics. Interaction 20 of somatostatin analogs with Somatostatin receptors expressed in this system subsequently affects cellular functionality of – 50 – WO99/65508 PCT/IL99/00329 BON-1. It was found that preferred backbone cyclic analogs of the present invention inhibit cAMP production following Forskolin stimulation. In this signal transudation pathway PTR 3173 is equipotent to clinically used drug Octreotide. 5 B. In-vitro cell-growth Inhibition by the backbone cyclic somatostatin analog PTR 3173: Pharmacological evaluation of growth inhibition was performed utilizing CHO cells expressing human cloned SST-R5. PTR 3173 10 recognition of SST-R5 at the cellular level was associated with considerably higher potency of growth inhibition compared to the native hormone and the drug Octreotide. C. Inhibition of Chromogranin A release by the backbone 15 cyclic somatostatin analog PTR 3173: Assessment of Chromogranin A release from BON-1 is an important assay aimed at identifying potential anti Carcinoid drugs. Chromogranin A is one of the principal mediators in degranulation of tumor granules, which secrete excessive 20 amounts of vasoactive substances from Carcinoid tumors. PTR 3173 possesses a significant anti-release effect on this pathway. One of the most intriguing findings of the backbone cyclic analog in the human BON-1 assay, is its equivalent potency with the native hormone Somatostatin, indicating a 25 potential beneficial effect in Carcinoid syndrome. Example 6: Comparison of PTR 3173, Octreotide and SRIF for binding to Non-Somatostatin G-coupled receptors. 30 Somatostatin receptors belong to the seven transmembrane G-protein coupled receptors super family. G-protein coupled receptors are widely distributed in the body and mediate physiological activities of various hormones such as Adrenaline, Acetylcholine, Opiates, Neurokinins, Gastrin, and 35 many other hormones. A drug candidate could be recognized by – 51 – WO99/65508 PCT/IL99/00329 a defined subtype of intra-family receptors. However, it could cause potential adverse effects in the body due to recognition of other receptors distinct from its family. This consideration raised the importance of inter- versus intra 5 receptor selectivity, in the context of developing physiological selective drugs. NovaScreen (Hanover, MD) performed an assessment for nonspecific binding to various G-protein coupled receptor families. Binding studies to Neurokinin, Opiate and 10 Muscarinic receptors were based on a comparison between the native hormone Somatostatin, Octreotide and PTR 3173. In a screening assay performed by Novascreen, significant high affinity of Octreotide to Opiate receptors was found, while under the same experimental conditions PTR 3173 and the 15 native hormone Somatostatin did not bind to these receptors (Figure 2). Significant higher affinity of Octreotide above PTR 3173 and the native hormone was also found to the Muscarinic-2 receptor. The significance of cross reactive binding of Octreotide to 20 the Opiate receptors was further investigated in the Guinea Pig Ileum. Preliminary results confirm the effect of Octreotide as an Opiate antagonist, while under the same experimental conditions PTR 3173 did not affect met-Enkephalin-evoked twitch contraction. 25 Example 7: The in-vivo effect of receptor-specific backbone cyclic somatostatin analogs on growth hormone release. Methods: 30 Inhibition of growth hormone (GH) release as a result of peptide administration was measured in Wistar male rats. The analog activity was compared in this study to SRIF or to Octreotide using 4 rats in each group. Adult male Wistar rats weighing 200-250 g, were maintained on 35 a constant light-dark cycle (light from 8:00 to 20:00 h), – 52 – WO99/65508 PCT/IL99/00329 temperature (21±3oC), and relative humidity (55±10%). Laboratory chow and tap water were available ad libitum. On the day of the experiment, rats were anesthetized with Nembutal (IP, 60 mg/kg). Ten minutes after anesthesia, drugs 5 were administrated S.C. at 0.01-100 microgram/kg dose. Stimulation of GH was performed by I.V. administration of 0.5 g/kg of L-Arginine through femoral vein. Sampling was carried out following 5 minutes of stimulation, at 15 or 30 minutes after peptide administration. Blood samples were collected 10 form abdominal vena-cava into tubes containing heparin (15 units per ml of blood) and centrifuged immediately. Plasma was separated and kept frozen at -20oC until assayed. Rat growth hormone (rGH) [125I] levels were determined by means of a radioimmunoassay kit (Amersham). The standard in 15 this kit has been calibrated against a reference standard preparation (NIH-RP2) obtained from the National Institute of Diabetes and Digestive and Kidney Diseases. All samples were measured in duplicate. The results of these experiments are shown in Figure 3. 20 Results: Growth hormone release was stimulated in rats using intravenous (IV) bolus administration of L-arginine under Nembutal anesthesia. The reported ED50 for Octreotide (Bauer, et al. ibid.) in this model is approximately 0.1 micrograms 25 per kilogram. Consequently, Octreotide and the tested receptor-specific backbone cyclic analogs were administered at a relatively high dose of 100 micrograms per kilogram. Under these experimental conditions PTR-3205 and PTR 3173 were equipotent inhibitors of growth hormone release in 30 comparison to Octreotide (Figure 3). Intriguing results were found with PTR-3201, which is a receptor 5 specific analog. This selective analog did not affect growth hormone release thus demonstrating that growth hormone inhibition is not mediated by somatostatin receptor subtype 5. On the other 35 hand, the significant inhibition found with PTR-3205, which – 53 – WO99/65508 PCT/IL99/00329 is s selective to receptor subtype 2, indicate that this is the principal receptor, which mediates growth hormone inhibition. Therefore, we can deduce that the effect on growth hormone found with the drug Octreotide or PTR 3173 is 5 due to their recognition of receptor subtype 2. Additional results of GH inhibition by PTR 3132 compare to Octreotide are described in table 10. 10 Table 10: – Plasma growth hormone concentration (ng/ml) Control None Octreotide PTR-3123 1.03 0.48 10 10 0.46 0.56 6.37 10 2.7 0.46 7.4 10 4.54 0.43 10 10 0.43 10 10 0.61 10 Average 8.72 2.33 0.50 8.96 SE 1.28 0.87 0.03 0.67 Example 8: The in-vivo effect of receptor-specific backbone cyclic somatostatin analogs on glucagon release. 15 In-vivo determination of the release of glucagon as a result of peptide administration was measured in Wistar male rats. The analog activity was compared in this study to SRIF or to Octreotide using 4 rats in each group. Time course profiles for glucagon release under constant experimental conditions 20 were measured. Male Wistar rats were fasted overnight. Animals were anesthetized with Nembutal (IP, 60 mg/kg). Ten minutes after anesthesia, drugs were administrated S.C. at 0.01-100 microgram/kg dose. Stimulation of glucagon secretion was 25 performed by I.V. administration of L-Arginine, 0.5 g/kg, 5 minutes before blood collection from portal vein. Hormone – 54 – WO99/65508 PCT/IL99/00329 concentration was measured by RIA. The only statistically significant difference in glucagon levels compare to control was obtained with the high dose of 100 micrograms per kilogram of PTR 3173 (Figure 4), a 1000 5 fold higher dose in comparison to the ED50 of PTR 3173 on growth hormone release. These results emphasize this backbone cyclic analog significant physiological selectivity compared to Octreotide as summarized in Table 4 above. 10 Additional results of glucagon inhibition by PTR 3132 compare to Octreotide are described in table 11. Table 11: Plasma glucagon concentration (ng/ml) Control None Octreotide PTR-3123 189 18 20 58 76 9.5 89 52 145 32 62 20 37 20 70 84 131 37 87 44 20 20 67 Average 98.4 19.9 49.7 53.5 SE 21.6 4.6 11.6 12.0 15 Example 9: The in-vivo effect of receptor-specific backbone cyclic somatostatin analogs on insulin release. The inhibition of insulin release by Somatostatin analogs is well documented in the literature (Bauer, et al. ibid., Lamberts et al. 1996, ibid.). However, synthetic Somatostatin 20 analogs with a long duration of physiological activity were reported to be less active on insulin in comparison to their potent inhibition of growth hormone or glucagon release (Bauer, et al. ibid., Lamberts et al. 1996, ibid.). Sandoz claims that there is physiological selectivity of Octreotide 25 on growth hormone versus insulin. However, in Type 2 diabetes – 55 – WO99/65508 PCT/IL99/00329 the long acting analog Octreotide suppresses of insulin and glucagon release, leaving glucose levels either unchanged or somewhat elevated. Other clinical trials have shown that the failure of 5 Octreotide to diminish glycemic values in Type 2 diabetes in spite of its ability to lower glucagon and growth hormone was probably dependent on temporary blockade of residual endogenous insulin secretion induced by its administration. In healthy subjects the administration of Octreotide resulted 10 in the development of mild fasting hyperglycemia and marked fasting hypoinsulinemia. Furthermore, Octreotide is prescribed for the treatment of nesidioblastosis, a syndrome associated with excessive release of insulin from the pancreas, which emphasizes Octreotide’s physiological 15 nonspecific effect on insulin (Kane et al. J. Clin. Inves. 100:1888, 1997). In order to evaluate the physiological effects of receptor specific backbone cyclic somatostatin analogs on insulin release, the same experimental protocol used by Sandoz for 20 the evaluation of Octreotide was performed. Insulin stimulation was induced by IV bolus administration of D-glucose to overnight fasted rats. Method: An in-vivo determination of insulin release as a result of 25 peptide administration was measured in Wistar male rats. The analog activity was compared in this study to SRIF or to Octreotide using 4 rats in each group. Time course profiles for GH release under constant experimental conditions were measured. 30 Male Wistar rats were fasted overnight. Animals were anesthetized with Nembutal (IP, 60 mg/kg). Ten minutes after anesthesia, drugs were administrated S.C. at 0.01-100 microgram/kg dose 30 minutes before stimulation of insulin secretion performed by I.V. administration of 0.5 g/kg of 35 D-glucose, 5 minutes before blood collection from abdominal – 56 – WO99/65508 PCT/IL99/00329 Vena-cava. Hormone levels were measured by RIA. Results: 5 PTR-3205 and Octreotide were both active inhibitors of insulin release (Figure 5a). The ED50 of Octreotide following subcutaneous injection was between 10 to 100 micrograms per kilogram, in accordance with the ED50 reported by Sandoz- 26 micrograms per kilogram. The significant effect found with 10 PTR-3205, indicates that Somatostatin receptor subtype 2 mediates the effect on growth hormone and also on insulin. This receptor-effector relationship was correlated with previous published data which indicated that somatostatin inhibits p-cell secretion via receptor subtype 2 in the 15 isolated perfused human pancreas. In contrast to the significant effect found PTR-3205 and Octreotide, high doses (100 micrograms per kilogram) of PTR-3201 and PTR 3173 – were inactive on insulin. It should be noted that to PTR 3173 in a similar dose had a significant effect on the release of 20 growth hormone. This intriguing physiological selectivity of PTR 3173 led us to repeat this experiment with a much higher dose of up to 1 milligram per kilogram. Under these experimental conditions, PTR 3173 was defined as a physiologically selective Somatostatin analog with no 25 appreciable effect on insulin in comparison to the drug Octreotide (Figure 5b). Additional results of glucagon inhibition by PTR 3132 compare to Octreotide are described in table 12. 30 – 57 – WO99/65508 PCT/IL99/00329 Table 12: Plasma insulin concentration (ng/ml) Control None Octreotide PTR-3123 3.97 1 3.5 1.46 4.14 2.5 1.95 5.66 5.12 0.7 3.7 3.8 0.74 3.06 2.44 2.7 2 1.87 3 1.1 2.8 1.5 Average 3.46 1.24 2.55 2.85 SE 0.44 0.43 0.42 0.74 Example 10: Additional preferred backbone cyclic somatostatin 5 analogs. Additional preferred somatostatin analogs that were synthesized are described in tables 13 and 14. – 58 – WO 99/65508 PCT/IL99/00329 Table 13: Additional somatostatin analogs. PTR No. Sequence 3102 NMeAla-Tyr-(D)Trp-Lys-Val-Phe(C3)-NH2 3135 (D)Phe-Phe-Phe(N2)-(D)Trp-Lys-Thr-Phe(C3)-Thr-NH2 3137 (D)Phe(N2)-Phe-Phe(C3)-(D)Trp-Lys-Thr-Phe-Thr-NH2 3139 H-(D)Phe-Ala(N3)-Phe-(D)Trp-Lys-Phe-Ala(C3)-Thr-NH2 3141 (D)Nal-Gly(S2)*-Tyr-(D)Trp-Lys-Val-Cys*-Thr-NH2 3143 Phe(C1)-Phe-(D)Trp-Lys-(D)Thr-Phe(N2)-NH2 3145 Phe-Phe-His-(D)Trp-Lys-Thr-Phe(C3)-Thr-NH2 3147 Ala-Phe-His-(D)Trp-Lys-Thr-Phe(C3)-Thr-NH2 3153 (D)Ala-Phe-His-(D)Trp-Lys-Thr-Phe(C3)-Thr-NH2 3155 (D)Phe-Phe-His-(D)Trp-Lys-Thr-Phe(C3)-Thr-NH2 3157 Aib-Phe-His-(D)Trp-Lys-Thr-Phe(C3)-Thr-NH2 3161 (D)Phe-Orn*-Phe-(D)Trp-Lys-Thr-Phe(C3)-Thr-OL 3163 (D)Phe-Phe(C3)-Phe-(D)Trp-Lys-Thr-DAP*-Thr-OL 3165 (D)Phe-Phe(C3)-Phe-(D)Trp-Lys-Thr-Lys*-Thr-OL 3187 Phe(C1)-Phe-Leu-(D)Trp-(D)Lys-Phe(N2)-NH2 3189 H-Ala(C3)-Phe-(D)Trp-Lys-Phe-Ala(C3)-Thr-NH2; bridge-piperazine 3191 H-Ala(C3)-Phe-(D)Trp-Lys-Phe-Ala(C3)-Thr-NH2 bridge-l, 2 diaminocyclohexane 3193 H-Ala(C3)-Phe-(D)Trp-Lys-Phe-Ala(C3)-Thr-NH2 bridge-m-xylenediamine 3195 H-Ala(C3)-Phe-(D)Trp-Lys-Phe-Ala(C3)-Thr-NH2 bridge-ethylene diamine The asterisk designates that the bridging group is connected between the Na-w-functionalized derivative of an amino acid and the side chain of the marked residue. 5 For the last 4 analogs (PTR 3189, 3191, 3193, and 3195), two identical building units are connected by the different diamine bridges as indicated. – 59 – WO99/65508 PCT/IL99/00329 Table 14: Additional somatostatin analogs. Position in SRIF sequence 5 6 7 8 9 10 11 12 Phe* Phe (D)Trp Lys Thr Phe(C2) Phe* (D)Trp Lys Thr Phe(C2) Phe* (D)Trp (D)Lys Thr Phe(C2) Ala(C1) (D)Trp Lys Ala(N2) Phe Ala(C1) (D)Trp Lys Thr Phe(N2) Ala(C1) (D)Trp Lys Thr Ala(N2) Ala(C1) Phe (D)Trp Lys Thr Ala(N2) Ala(C1) Tyr (D)Trp Lys Val Phe (N2) Ala* Phe (D)Trp (D)Lys Thr Ala(N2) (D)Phe Ala(C1) Phe (D)Trp Lys Ala(N2) Ala* (D)Trp Lys Thr Ala(C2) Ala(S2) (D)Trp Lys Thr Cys Ala(S2) (D)Trp Lys Thr Cys Thr-Ol Ala(S2) Phe (D)Trp Lys Cys Ala(S2) Phe (D)Trp Lys Thr Cys Thr-Ol the asterisk denotes that the bridging group is connected between the Na-w-functionalized derivative of an amino acid and the N terminus of the peptide. The Thr residues at 5 position 12 in PTR 3965 and PTR 3975 are preferably reduced to a terminal alcohol group. Example 11. Additional preferred backbone cyclized somatostatin analogs containing SH-Building Units. 10 Additional preferred analogs which contain at list one SH-type building units are listed in table 12 with their binding affinities to SST-Rs. The asterisks in each PTR – 60 – WO 99/65508 PCT/IL99/00329 sequence designate the places of cyclization. The bridging group is connected between the marked Na-w-S-functionalized derivative of an amino acid and another marked N a–S-functionalized derivative of an amino acid, the side 5 chain of Cys residue, or another SH-moiety. Table 15: Additional preferred analogs containing SH-type building units. PTR Sequence ICs50 (nM) for SST-R 3159 Fmoc-Gly(S 1)-Phe-(D)Trp-Lys-Thr-Cys-Thr-OL 1 2 3 5 3167 (D)Phe-Gly(Sl)-(D)Trp-Lys-Thr-Cys*-Thr-OL 3169 GIy(S 1)-(D)Trp-Lys-Thr-Cys*-Thr-OL 3175 Phe(S4)-Tyr-(D)Trp-Lys-Val-Cys*-Thr-NH2 3177 Phe(S4)-Tyr-(D)Trp-Lys-Val-Cys*-Trp-NH2 3179 Fmoc-Gly(S l)-Tyr-(D)Trp-Lys-Val-Cys*-Thr-NH2 3181 Fmoc-Gly(S 1)-Tyr-(D)Trp-Lys-Val-Cys*-Trp-NH2 3197 Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)*-NH2 1000 4 40 1 3207 (D)Phe-Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)*-NH2 >333 1-12 4 3211 Mercapto-acetic-acid(*)-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)* 333 37 12-37 1.3
-NH
2 3213 Gly(S2)*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)*-NH2 333 4 333 12 3217 3-Thiopropanoic-acid*-Phe-Trp-(D)Trp-Lys-Thr-Phe- >333 37 100 4.1 Gly(S2)*-NH 2 3219 (D)Phe-Gly(S2)*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)*-NH2 >333 4 333 37 3221 (D)Nal-Gly(S2)*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)*-NH2 >333 12 333 111 10 The present invention has been exemplified herein by means of certain non-limitative examples. It will be clear to the skilled artisan that many further modifications and variations to the preferred embodiments are possible, without 15 departing from the scope of the invention, which is to be construed by the scope of the claims which follow. – 61 –

Claims (30)

3. The backbone cyclized somatostatin analog of claim 2 5 wherein: Q is hydrogen; R 5 is GABA; R 6 is Phe; R 7 is Trp; 10 R is (D)Trp; R 9 is Lys; R 10 is Thr; R 11 is Phe; R 12 is Gly; 15 n is 3; and X is an amide.

4. The backbone cyclized somatostatin analog of claim 2 wherein: 20 Q is galactose; R 5 is Dab; R 6 is Phe; R is (L)-Trp; R is (D) Trp; 25 R 9 is Lys; R 10 is Thr; R 11 is Phe; R is Gly; n is 3; and 30 X is amide.

5. The backbone cyclized somatostatin analog of claim 1, having the general Formula 8: – 63 – WO 99/65508 PCT/IL99/00329 NR-7_ (D) Trp-Lys-Rio-Ru-NR12-X 5 (CH 2 ) m-Y- (CH2) n Formula No. 8 wherein: m and n are 1 to 5 10 X designates a terminal carboxy acid, amide or alcohol group; R is(D)- or (L)-Phe, or (D)- or (L)-Ala; R is Tyr, (D)- or (L)- Ala, or (D)- or (L)- Phe; R i is Thr, Val, Ser, or Cys; 15 Ru is Val, (D)- or (L)-lNal, (D)- or (L)-2Nal , or (D) or (L)-Phe; R 12 is Gly, (D)- or (L)-Ala, or (D) or (L)-Phe; and Y is amide, thioether, thioester or disulfide. 20 6. The backbone cyclized somatostatin analog of claim 5 wherein: R 6 is(D)- or (L)-Phe; R 7 is Tyr or Phe; R i0 is Thr, Val or Ser; 25 Ru is Val, INal or 2Nal; R 12 is Gly; and Y is amide.

7. The backbone cyclized somatostatin analog of claim 1, 30 having the general Formula 9: NR 6-R -R -Lys-R R -R12-X S(CH 2 )m-Y- (CH 2 ) n 35 Formula No. 9 wherein: m and n are 1 to 5 X designates a terminal carboxy acid, amide or alcohol 40 group; R 6 is(D)- or (L)-Phe, or (D)- or (L)-Ala; – 64 – WO 99/65508 PCT/IL99/00329 R 7 is Tyr or (D)- or (L)- Phe; R is (D)- or (L)- Trp, (D)- or (L)-1Nal or (D)- or (L)-2Nal; R 10 i is Thr, Val, Ser, or Cys; 5 Ru is Gly or (D) or (L)-Phe; R 12 is Thr, GABA, (D)- or (L)-lNal, (D)- or (L)- 2Nal, or (D) or (L)-Phe; and Y is amide, thioether, thioester or disulfide. 10 8. The backbone cyclized somatostatin analog of claim 7 wherein: R is(D)- or (L)-Phe; R 7 is Tyr; R 8 is (D)Trp, (D) 1Nal or (D)2Nal; 15 R i0 is Val; Ru is Gly; R is Thr, iNal or 2Nal; and Y is amide. 20 9. The backbone cyclized somatostatin analog of claim 1, having the general Formula 10: 4_ 5_6 7_8- 9 10 11 12 R -E R -R R-R R R -R 12-X 25 (CH 2 ) mY (CH 2 ) n Formula No. 10 wherein m and n are 1 to 5; 30 X designates a terminal carboxy acid, amide or alcohol group; R is hydrogen or a terminal group of one to four amino acids; R 5 is iNal, 2Nal, P-Asp (Ind), Gly, Tyr, (D)- or 35 (L)-Ala, or (D)- or (L)-Phe; R6 is a bond, or Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe; R is a bond, or 6ly, Tyr, (D)- or (L)-Ala, or (D)- or – 65 – WO 99/65508 PCT/IL99/00329 (L) -Phe; R is (D)- or (L)-Trp; R 9 is (D)- or (L)-Lys; R 10 is a bond or Gly, Abu, Cys, Thr, Val, (D)- or 5 (L)-Ala, or (D)- or (L)-Phe; R’ is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe; R 12 is a bond or Val, Thr, iNal or 2Nal; and Y is amide, thioether, thioester or disulfide. 10 10. The backbone cyclized somatostatin analog of claim 9 wherein: R 4 is hydrogen; R 5 is (D)- or (L)-Phe, or (D)- or (L)-Ala; R 6 is a bond or (D)- or (L)-Phe, Ala or Tyr; 15 R 7 is (D)- or (L)-Phe, Ala or Tyr; R 10 is a bond or Thr, Val or (D)- or (L)-Phe; R” is (D)- or (L)-Ala, or (D)- or (L)-Phe; and R is a bond. 20 11. The backbone cyclized somatostatin analog of claim 10 wherein: R 5 is (D)- or (L)-Ala, or (D)- or.(L)-Phe; R 6 is a bond or (D)- or (L)-Ala, or (D)- or (L)-Phe; R 7 is (D)- or (L)-Ala, or (D)- or (L)-Phe; 25 R1 is a bond or Thr, Cys, (D)- or (L)- Ala; R 11 is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe; and R is a bond or Thr.

12. The backbone cyclized somatostatin analog of claim 1, 30 having the general Formula 11: 5 6 7 8 9 10 11 NR-R-R _-R -R R I R -X L (CH 2 )m-y (CH 2 )n 35 Formula No. 11 wherein: m and n are 1 to 5 – 66 – WO 99/65508 PCT/IL99/00329 R 5 is (L)- or (D)- Phe, Tyr or (D)- or (L)- Ala; R 6 is (L)- or (D)- Phe, Tyr or (D)- or (L)- Ala; R is absent or (L or D)- Phe, Tyr or (D or L)- Ala; R 8 is (D)- or (L)-Trp; 5 R 9 is (D)- or (L)-Lys; R1 ° is a bond or Thr, Val, Cys or (D)- or (L)-Ala; R” is (L) or (D)-Phe, Cys, or (D)- or (L)-Ala; Y is amide, thioether, thioester or disulfide. 10 13. The backbone cyclized somatostatin analog of claim 12 wherein: R is (D)- or (L)-Ala; R 7 is a bond or (D)- or (L)-Phe; R 10 i is Thr; 15 R” is Cys; and X is an alcohol group.

14. The backbone cyclized somatostatin analog of claim 1, having the general Formula 12: 20 NR6-NR -(D or L)Trp-(D or L)Lys-Rio-NR -NR12 (CH 2 )m-Y- (CH 2 )n 25 Formula No. 12 wherein: the dotted line indicates that the bridge is connected to NR 6 30 or NR at one end and to NRu or NR 12 at the other end; R is hydrogen or (D)- or (L)-Phe or Ala; R 7 is (D)- or (L)-Phe, Ala or Tyr; R 8 is Thr, Ala, Val or Cys; Ru is a bond or (D)- or (L)-Phe, Ala, or Cys; 35 R 12 is a bond or Thr or Thr reduced to an alcohol; and Y is amide, thioether, thioester or disulfide. Preferably, the bridge. is connected to NR 6 and NR 11 or to NR 6 – 67 – WO 99/65508 PCT/IL99/00329 and NR 12 with R 12 being Thr reduced to an alcohol.

15. The backbone cyclized somatostatin analog of claim 1, having the general Formula 13: 5 Cys-R -R 7- (D) Trp-Lys-Rio-R -NR 12-X (CH 2 )m-Y- (CH 2 ) n 10 Formula No. 13 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; 15 R is (D)- or (L)-Phe or Tyr; R is (D)- or (L)-Trp,(D)- or (L)-Phe, (D)- or (L)- INal or (D)- or (L)- 2Nal, or Tyr; R10 is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe; 20 Ru is (D)- or (L)-Phe or (D)- or (L)-Ala; R is Gly, Val, or (D)- or (L)-Phe; and Y is thioether, thioester or disulfide.

16. The backbone cyclized somatostatin analog of claim 15 25 wherein: R is Phe; R 7 is Trp; R 10 is Thr; Ru is Phe; 30 R 12 is Gly; and Y is disulfide.

17. The backbone cyclized somatostatin analog of claim 1, having the general Formula 14: – 68 – WO 99/65508 PCT/IL99/00329 R -Cys-R 6-R’ – (D) Trp-Lys-R 1-R -NR12-X 5 (CH 2 ) m-Y- (CH 2 ) Formula No. 14 wherein m and n are 1 to 5; 10 X designates a terminal carboxy acid, amide or alcohol group; R 4 is (D)- or (L)-Phe or Tyr; R 6 is (D)- or (L)-Phe or Tyr; R is (D)- or (L)-Trp,(D)- or (L)-Phe, (D)- or (L)- iNal 15 or (D)- or (L)- 2Nal, or Tyr; R 10 is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe; Ru is (D)-or (L)-Phe or (D)-or (L)-Ala; R 12 is Gly, Val, or (D)- or (L)-Phe; and 20 Y is thioether, thioester or disulfide.

18. The backbone cyclized somatostatin analog of claim 17 wherein: R 4 is (D)Phe; 25 R is Phe; R 7 is Trp; R 10 is Thr; Ru is Phe; R 1 2 is Gly; and 30 Y is disulfide.

19. The backbone cyclized somatostatin analog of claim 1, having the general Formula 15: – 69 – WO 99/65508 PCT/IL99/00329 NR -Cys-R – (D) Trp-Lys-Ro-Cys-R12-NR3-X (CH 2 )m-Y- (CH 2 ) n Formula No. 15 10 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; R 5 is (D)- or (L)-Phe or (D)- or (L)-Ala; R is (D)- or (L)-Trp,(D)- or (L)-Phe, (D)- or (L)- iNal 15 or (D)- or (L)- 2Nal, or Tyr; R1 0 is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe; R is Gly, Val, or (D)- or (L)-Phe; R13 is (D)- or (L)-Phe or (D)- or (L)-Ala; and 20 Y is amide, thioether, thioester or disulfide.

20. The backbone cyclized somatostatin analog of claim 19 wherein: R 5 is Phe; 25 R 7 is Phe; R”) is Thr; R 12 is Gly, Val, or (D)- or (L)-Phe; R 13 is Phe; and Y is amide. 30

21. A backbone cyclized somatostatin analog of claim 1 having the formula: Phe*-Phe-Phe-(D)Trp-(D)Lys-Phe(C2)-X Phe(Cl) -Phe-Phe-(D)Trp-Lys-Phe(N2)-X Phe(Cl) -Phe-Phe-(D)-Trp-(D)Lys-Phe(N2)-X – 70 – WO99/65508 PCT/IL99/00329 Phe(N2)-Tyr-(D)2Nal-Lys-Val-Gly(C2)-Thr-X Phe(N2)-Tyr-(D)Trp-Lys-Val-Gly(C2)-2Nal-X Phe(N2)-Tyr-(D)Trp-Lys-Val-Val-Gly(C2)-X Phe(N2)-Tyr-(D)Trp-Lys-Ser-2Nal-Gly(C2)-X Phe(N2)-Phe-(D)Trp-Lys-Thr-2Nal-Gly(C2)-X GABA*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X Phe(C3)-Cys*-Phe-(D)Trp-Lys-Thr-Cys*-Phe-Phe(N3)-X (D)Phe-Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X Galactose-Dab*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X where X is designates a terminal carboxy acid, amide or alcohol group; the asterisk denotes that the bridging group is connected between the Na~-a-functionalized derivative of an 5 amino acid and the N-terminus of the peptide or the side chain of the Cys residue.

22. A pharmaceutical composition comprising a backbone cyclized somatostatin analog that incorporates at least 10 one building unit, said building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester or disulfide, wherein the at least one building unit is connected via said bridging group to form a cyclic 15 structure with a moiety selected from the group consisting of a second building unit, the side chain of an amino acid residue of the sequence or the N-terminal amino acid residue and a pharmaceutically acceptable carrier. 20

23. The pharmaceutical composition of claim 22 wherein the somatostatin analog is according to claim 2.

24. The pharmaceutical composition of claim 22 wherein the 25 somatostatin analog is according to claim 5. – 71 – WO99/65508 PCT/IL99/00329

25. The pharmaceutical composition of claim 22 wherein the somatostatin analog is according to claim 7.

26. The pharmaceutical composition of claim 22 wherein the 5 somatostatin analog is according to claim 9.

27. The pharmaceutical composition of claim 22 wherein the somatostatin analog is according to claim 12. 10 28. The pharmaceutical composition of claim 22 wherein the somatostatin analog is according to claim 14.

29. The pharmaceutical composition of claim 22 wherein the somatostatin analog is according to claim 15. 15

30. The pharmaceutical composition of claim 22 wherein the somatostatin analog is according to claim 17.

31. The pharmaceutical composition of claim 22 wherein the 20 somatostatin analog is according to claim 19.

32. The pharmaceutical composition of claim 22 wherein the somatostatin analog is according to claim 21. 25 33. The composition according to claim 22 wherein the backbone cyclic analog is selective for one somatostatin receptor subtype.

34. The composition according to claim 22 wherein the 30 backbone cyclic analog is selective for two somatostatin receptor subtypes.

35. A method for treating or preventing of disorders selected from the group consisting of cancers, 35 autoimmune diseases, endocrine disorders, diabetic-associatbd complications, gastrointestinal – 72 – WO99/65508 PCT/IL99/00329 disorders, inflammatory diseases, pancreatitis, atherosclerosis, restenosis and post-surgical pain, comprising administering to a mammal in need thereof a pharmaceutical composition comprising a therapeutically 5 effective amount of a backbone cyclized somatostatin analog according to claim 1.

36. The method according to claim 36 wherein the backbone cyclic analog is selective for one somatostatin receptor 10 subtype.

37. The method according to claim 36 wherein the backbone cyclic analog is selective for two somatostatin receptor subtypes. 15

38. A method for diagnosing cancer comprising administration of a backbone cyclized somatostatin analog of claim 1.

39. The method according to claim 38 wherein the backbone 20 cyclic analog is used for imaging the existence of metastases.

40. The method according to claim 38 wherein the backbone cyclic analog is labeled with a detectable probe. 25 – 73 –

AU42884/99A
1998-06-19
1999-06-15
Conformationally constrained backbone cyclized somatostatin analogs

Ceased

AU747515B2
(en)

Applications Claiming Priority (5)

Application Number
Priority Date
Filing Date
Title

US09/100360

1998-06-19

US09/100,360

US6051554A
(en)

1995-06-07
1998-06-19
Conformationally constrained backbone cyclized somatostatin analogs

US09/203,389

US6355613B1
(en)

1996-07-31
1998-12-02
Conformationally constrained backbone cyclized somatostatin analogs

US09/203389

1998-12-02

PCT/IL1999/000329

WO1999065508A1
(en)

1998-06-19
1999-06-15
Conformationally constrained backbone cyclized somatostatin analogs

Publications (2)

Publication Number
Publication Date

AU4288499A
true

AU4288499A
(en)

2000-01-05

AU747515B2

AU747515B2
(en)

2002-05-16

Family
ID=26797065
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU42884/99A
Ceased

AU747515B2
(en)

1998-06-19
1999-06-15
Conformationally constrained backbone cyclized somatostatin analogs

Country Status (13)

Country
Link

US
(3)

US6355613B1
(en)

EP
(1)

EP1085896B1
(en)

JP
(1)

JP4637352B2
(en)

KR
(1)

KR100689402B1
(en)

AT
(1)

ATE362371T1
(en)

AU
(1)

AU747515B2
(en)

CA
(1)

CA2335488C
(en)

DE
(1)

DE69936100T2
(en)

DK
(1)

DK1085896T3
(en)

ES
(1)

ES2288029T3
(en)

IL
(1)

IL139956A0
(en)

NZ
(1)

NZ508956A
(en)

WO
(1)

WO1999065508A1
(en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US6841533B1
(en)

1995-12-07
2005-01-11
Peptor Limited
Conformationally constrained backbone cyclized interleukin-6 antagonists

US6355613B1
(en)

1996-07-31
2002-03-12
Peptor Limited
Conformationally constrained backbone cyclized somatostatin analogs

CA2284459C
(en)

1999-10-04
2012-12-11
Neokimia Inc.
Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery

GB0018891D0
(en)

2000-08-01
2000-09-20
Novartis Ag
Organic compounds

AU2001288847A1
(en)

2000-09-07
2002-03-22
Biosyntema Inc.
Conformationally constrained labeled peptides for imaging and therapy

IL156506A0
(en)

2001-01-12
2004-01-04
Sod Conseils Rech Applic
Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof

CZ299362B6
(en)

2001-03-08
2008-07-02
The Administrators Of The Tulane Educational Fund
Somatostatin antagonists

CA2443085A1
(en)

2001-04-09
2002-10-17
David H. Coy
Somatostatin agonists

EP1283216A1
(en)

2001-08-10
2003-02-12
Mallinckrodt Inc.
Somatostatin analogues binding to all somatostatin receptor subtypes and their use

US7189856B2
(en)

2001-12-28
2007-03-13
Gideon Shapiro
Non-peptide somatostatin receptor ligands

IL148921A0
(en)

2002-03-26
2002-09-12
Peptor Ltd
Photo active backbone cyclized somatostatin analogs for optical imaging and photodynamic therapy

IL150384A0
(en)

2002-06-24
2002-12-01
Peptor Ltd
Radiolabelled somatostatin analogs backbone cyclized through metal complexation

WO2005012332A1
(en)

2003-07-31
2005-02-10
Tranzyme Pharma
Spatially-defined macrocycles incorporating peptide bond surrogates

GB0318682D0
(en)

2003-08-08
2003-09-10
Novartis Ag
Organic compounds

ITFI20040057A1
(en)

2004-03-10
2004-06-10
Mauro Giuntini

ANALOGS OF THE SOMATOSTATINA

US20050287557A1
(en)

2004-05-10
2005-12-29
Suad Efendic
Methods for identifying compounds for treating diabetes mellitus

US20070025910A1
(en)

2005-07-29
2007-02-01
Norenberg Jeffrey P
Anticancer therapy

CA2642479C
(en)

2006-02-15
2014-08-19
Intec Pharma Ltd.
A gastro-retentive system for the delivery of macromolecules

CN1904150B
(en)

2006-08-01
2010-07-28
华东师范大学
Human glucagon peptide/derivative and its solid phase chemical synthesis

EP2188016B1
(en)

2007-09-11
2012-08-01
Mondobiotech Laboratories AG
Use of octreotide as a therapeutic agent

WO2011024175A1
(en)

2009-08-28
2011-03-03
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Macrocyclic compounds, compositions comprising them and methods for preventing or treating hiv infection

EP2604281B1
(en)

2011-12-14
2014-07-30
Centre National de la Recherche Scientifique (CNRS)
Clicked somatostatin conjugated analogs for biological applications

EP2807182A1
(en)

2012-01-23
2014-12-03
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
Stabilized peptide helices for inhibiting dimerization of chemokine c motif receptor 2 (ccr2)

US9371282B2
(en)

2013-05-17
2016-06-21
Centrexion Therapeutics Corporation
Somatostatin receptor subtype 4 (SSTR4) agonists

WO2015087334A1
(en)

2013-12-15
2015-06-18
Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd.
Viperistatin-derived peptides and uses thereof

EP3135686A1
(en)

2015-08-28
2017-03-01
Latvian Biomedical Research and Study Centre
Novel recombinant cyclized human growth hormone

WO2017125933A1
(en)

2016-01-21
2017-07-27
Ramot At Tel-Aviv University Ltd.
Formation of functionalized nanoparticles by supramolecular co-assembly

CN109462982A
(en)

2016-02-16
2019-03-12
斯特朗布里奇都柏林有限公司
Dimension Doreptide under physiological condition with poor solubility is for treating acromegalia, acromegalia cancer, SST-R5 expression type tumour, type-2 diabetes mellitus, hyperglycemia and hormone related neoplasms

US10662225B2
(en)

2016-06-07
2020-05-26
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Backbone cyclized inhibitory peptides of myeloid differentiation factor 88 (MyD88)

US11261215B2
(en)

2017-09-19
2022-03-01
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Somatostatin prodrugs

EP3927737A1
(en)

2019-02-21
2021-12-29
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Par4 derived peptides, analogs and uses thereof

WO2022003673A1
(en)

2020-06-30
2022-01-06
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Humanin analogs and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4011182A
(en)

1975-03-21
1977-03-08
American Home Products Corporation
Cyclic undecapeptide analogs of somatostatin and intermediates

US3988304A
(en)

1975-08-25
1976-10-26
American Home Products Corporation
Cyclic dodecapeptide derivatives of somatostatin and intermediates thereof

US4054558A
(en)

1976-05-24
1977-10-18
American Home Products Corporation
Cyclic dodecapeptide and intermediates therefor

SU798098A1
(en)

1977-12-14
1981-01-23
Ордена Трудового Красного Знамениинститут Органического Синтезаан Латвийской Ccp
Cyclic analog of bradykinin possessing ability of creating prolongated depressing effect in vivo experiment and vascular permeability in situ experiment

US4191754A
(en)

1979-02-28
1980-03-04
Merck & Co., Inc.
Bicyclic somatostatin analogs

US4235886A
(en)

1979-10-31
1980-11-25
Merck & Co., Inc.
Cyclic hexapeptide somatostatin analogs

US4310518A
(en)

1979-10-31
1982-01-12
Merck & Co., Inc.
Cyclic hexapeptide somatostatin analogs

CY1327A
(en)

1979-11-27
1986-06-27
Sandoz Ag
Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use

US4369179A
(en)

1979-12-14
1983-01-18
Ciba-Geigy Corporation
Acylpeptides

DE3845000C2
(en)

1987-07-10
1998-11-19
Novartis Ag
Compsn. contg. somatostatin analogues for treating breast cancer

US4923963A
(en)

1987-09-02
1990-05-08
Nova Technology Limited Partnership
Bradykinin antagonist peptides

US5073541A
(en)

1987-11-18
1991-12-17
Administrators Of The Tulane Educational Fund
Treatment of small cell lung cancer with somatostatin analogs

EP0334244A3
(en)

1988-03-25
1991-05-29
The Procter & Gamble Company
Bradykinin antagonist peptides

EP0336779A3
(en)

1988-04-08
1991-08-21
Scripps Clinic And Research Foundation
Polypeptides stabilized by covalent hydrogen bond replacements

IE63490B1
(en)

1988-11-24
1995-05-03
Hoechst Ag
Peptides having bradykinin antagonist action

US5753627A
(en)

1988-12-05
1998-05-19
Novartis Ag
Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis

US5650489A
(en)

1990-07-02
1997-07-22
The Arizona Board Of Regents
Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof

HU207104B
(en)

1991-01-25
1993-03-01
Biosignal Kutato Fejlesztoe Kf
Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds

CA2102633A1
(en)

1991-06-03
1992-12-04
Peter H. Cox
Radiolabelled somatostatin derivatives, their preparation and use

DE4119544C1
(en)

1991-06-13
1992-10-15
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig, De

US5364851A
(en)

1991-06-14
1994-11-15
International Synthecon, Llc
Conformationally restricted biologically active peptides, methods for their production and uses thereof

US5225180A
(en)

1991-09-10
1993-07-06
Diatech, Inc.
Technetium-99m labeled somatostatin-derived peptides for imaging

US6117974A
(en)

1991-10-02
2000-09-12
Peptor Limited
Libraries of backbone-cyclized peptidomimetics

IL99628A
(en)

1991-10-02
2004-07-25
Yissum Res Dev Co
Processes for the preparation of cyclic peptides, and pharmaceutical compositions containing them

ATE203417T1
(en)

1992-02-05
2001-08-15
Mallinckrodt Inc

RADIOACTIVE LABELED SOMATOSTATIN

US5411943A
(en)

1992-02-25
1995-05-02
Biomeasure, Inc.
Hepatoma treatment with somatostatin analogs

US5620675A
(en)

1992-06-23
1997-04-15
Diatech, Inc.
Radioactive peptides

US5371070A
(en)

1992-11-09
1994-12-06
The Salk Institute For Biological Studies
Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins

NO940080L
(en)

1993-01-12
1994-07-13
Sandoz Ag

Polypeptides, methods of their preparation and pharmaceutical preparations thereof

EP0720621B1
(en)

1993-06-23
2001-02-07
Diatide, Inc.
Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses

US5449761A
(en)

1993-09-28
1995-09-12
Cytogen Corporation
Metal-binding targeted polypeptide constructs

IL109943A
(en)

1994-06-08
2006-08-01
Develogen Israel Ltd
Conformationally constrained backbone cyclized peptide analogs

US5597894A
(en)

1995-06-05
1997-01-28
The Louisiana State University Medical Center Foundation
Multi-tyrosinated somatostatin analogs

US5770687A
(en)

1995-06-07
1998-06-23
Peptor Limited
Comformationally constrained backbone cyclized somatostatin analogs

US6051554A
(en)

1995-06-07
2000-04-18
Peptor Limited
Conformationally constrained backbone cyclized somatostatin analogs

US6355613B1
(en)

1996-07-31
2002-03-12
Peptor Limited
Conformationally constrained backbone cyclized somatostatin analogs

US6025372A
(en)

1997-04-04
2000-02-15
Merck & Co., Inc.
Somatostatin agonists

US6335613B1
(en)

2000-12-04
2002-01-01
Abb T&D Technology Ltd.
Versatile power flow transformers for compensating power flow in a transmission line

1998

1998-12-02
US
US09/203,389
patent/US6355613B1/en
not_active
Expired – Lifetime

1999

1999-06-15
DE
DE69936100T
patent/DE69936100T2/en
not_active
Expired – Lifetime

1999-06-15
JP
JP2000554387A
patent/JP4637352B2/en
not_active
Expired – Fee Related

1999-06-15
NZ
NZ508956A
patent/NZ508956A/en
not_active
IP Right Cessation

1999-06-15
EP
EP99957020A
patent/EP1085896B1/en
not_active
Expired – Lifetime

1999-06-15
WO
PCT/IL1999/000329
patent/WO1999065508A1/en
active
IP Right Grant

1999-06-15
DK
DK99957020T
patent/DK1085896T3/en
active

1999-06-15
IL
IL13995699A
patent/IL139956A0/en
unknown

1999-06-15
CA
CA2335488A
patent/CA2335488C/en
not_active
Expired – Lifetime

1999-06-15
KR
KR1020007014431A
patent/KR100689402B1/en
not_active
IP Right Cessation

1999-06-15
ES
ES99957020T
patent/ES2288029T3/en
not_active
Expired – Lifetime

1999-06-15
AT
AT99957020T
patent/ATE362371T1/en
active

1999-06-15
AU
AU42884/99A
patent/AU747515B2/en
not_active
Ceased

2000

2000-12-13
US
US09/734,583
patent/US6930088B2/en
not_active
Expired – Fee Related

2004

2004-08-12
US
US10/916,522
patent/US7060679B2/en
not_active
Expired – Lifetime

Also Published As

Publication number
Publication date

US20020052315A1
(en)

2002-05-02

ATE362371T1
(en)

2007-06-15

KR20010071523A
(en)

2001-07-28

DK1085896T3
(en)

2007-09-10

ES2288029T3
(en)

2007-12-16

DE69936100D1
(en)

2007-06-28

JP2002518339A
(en)

2002-06-25

EP1085896A4
(en)

2005-04-06

AU747515B2
(en)

2002-05-16

CA2335488C
(en)

2011-08-23

US7060679B2
(en)

2006-06-13

US6930088B2
(en)

2005-08-16

WO1999065508A1
(en)

1999-12-23

JP4637352B2
(en)

2011-02-23

CA2335488A1
(en)

1999-12-23

US20050043226A1
(en)

2005-02-24

EP1085896A1
(en)

2001-03-28

EP1085896B1
(en)

2007-05-16

NZ508956A
(en)

2003-06-30

IL139956A0
(en)

2002-02-10

KR100689402B1
(en)

2007-03-08

US6355613B1
(en)

2002-03-12

DE69936100T2
(en)

2008-02-07

Contact information